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Abstract  
 
Liver injury stimulates hepatocyte proliferation, regenerating the liver through self-
replication. In cases where there is severe, repetitive, parenchymal damage, as seen in 
human chronic liver disease, hepatocyte mediated regeneration becomes impaired. In 
this setting it is currently unclear whether endogenous biliary epithelial cells can 
repopulate the hepatocyte compartment. This thesis therefore aimed to address this 
point by lineage tracing the main two liver epithelia populations on a background of 
impaired hepatocyte regeneration. 
 
To impair regeneration, an Itgb1 transgene was specifically deleted, conditionally, 
from the hepatocyte epithelium. Long-term loss of β1-Integrin alone or with additional 
injury caused an epithelial ductular reaction of biliary origin. Alongside β1-Integrin 
ablation, the hepatocyte epithelium was also labelled with a heritable 
ROSA26LSLtdTomato reporter. Impaired hepatocyte regeneration mediated by β1-
integrin ablation resulted in 25% of hepatocytes becoming tdTomato negative (non-
hepatocyte derived). To verify that the non-hepatocyte mediated regeneration was 
originating from the biliary epithelium, anti-Itgb1 RNAi was administrated to 
K19CreERT LSLtdTomato mice. Resulting in tdTomato positive hepatocytes that had 
differentiated from the labelled tdTomato positive biliary epithelial cells.  
 
In summary, this thesis demonstrates that hepatocyte β1-Integrin ablation combined 
with toxic damage causes marked ductular reactions and results in a substantial 
regeneration of functional hepatocytes from the biliary epithelium. 
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Lay abstract 
 
The liver is capable of repair after injury, normally this occurs through self-duplication 
of the resident liver cells. These liver cells are comprised from either the major 
functional cells of the liver, the hepatocytes, or the cells that form the liver bile ducts, 
the cholangiocytes. During human chronic liver disease, the hepatocytes lose the 
ability to divide to replace lost cells. When this occurs, it is unknown if the 
cholangiocytes in the bile ducts can become hepatocytes, acting as an alternative cell 
source for liver repair.  
 
In this thesis, I describe experiments performed in the mouse which confirm that 
cholangiocytes can become hepatocytes. I show this using genetic tools that allowed 
me to specifically label the distinct cell populations in the liver and track their fate 
after injury. Using this method, I found that cholangiocytes can significantly contribute 
to the formation of new hepatocytes when the original hepatocytes fail to replace 
themselves.  
 
This finding builds upon previous work that showed cholangiocytes have a therapeutic 
potential in chronic liver disease. By understanding the environment needed for 
cholangiocytes to become hepatocytes we can now develop therapies that could 
enhance cholangiocyte derived repair of the liver. 
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Liver Anatomy and Physiology  
The liver is a vital organ, performing multiple functions in the body including: glucose 
and lipid metabolism, hormone secretion, bile synthesis, and detoxification of 
ammonia or xenobiotic agents.  To execute these various functions, the cells of the 
liver are organised around a unique vasculature structure that has a dense fenestrated 
capillary network supplied with blood from both the portal vein and hepatic artery. 
These afferent vessels branch to smaller vessels forming portal tracts (PT) throughout 
the liver. Blood drains out of the liver through efferent central veins (CV) that tribute 
the hepatic vein. On a microstructural scale, blood flows along a portal tract to central 
vein axis, through the fenestrated capillaries, termed sinusoids (Figure 1.1a,b). 
Adjacent to the sinusoids are the major epithelial cells of the liver, the hepatocytes1. 
Polarised hepatocytes form an epithelial sheet between the sinusoids, with the basal 
surface of the cells exposed to blood flow via the fenestrated sinusoids2 (Figure 1.1c). 
Exposure to the circulating blood allows hepatocytes to carry out the aforementioned 
functions such as secreting serum proteins,  hormones and metabolising molecules 
absorbed from the intestine3. The apical surface of the hepatocyte forms a network of 
bile canaliculi with adjacent hepatocytes. Hepatocytes use transporter proteins to 
secrete bile salts, drug metabolites and other waste in to the bile canaliculi, which drain 
in to the bile ducts at the portal tract.  The bile ducts are formed from columnar, biliary 
epithelial cells (BEC), which share a common developmental progenitor with 
hepatocytes, the hepatoblast4,5.  The intrahepatic bile ducts connect with the wider 
biliary system via the common hepatic duct, which supplies bile to the duodenum.  
Hepatocytes distributed along the PT to CV axis are heterogeneous and form 3 zones 
along the axis, according to their function (Figure 1.1c). Changes in liver zonation 
correspond with changes in the blood oxygen concentration6 and, importantly, the 
WNT signalling gradient. Disruption of the WNT pathway by targeting either 
downstream canonical effectors or administering WNT inhibitors results in loss of 
liver zonation7–10. Arranged around the oxygen rich, WNT low PT, in an acinar 
formation, are the zone 1 hepatocytes. Zone 1 hepatocytes perform gluconeogenesis, 
are involved in the early steps of ammonia detoxification that include urea synthesis 
and have a higher concentration of glutathione, making the cells more resistant to 
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reactive oxygen species1. In contrast, the zone 3 hepatocytes situated in an acinar 
around the WNT high, oxygen low CV can express high levels of cytochrome P450 
giving them a high drug detoxification capacity. Zone 3 hepatocytes also express the 
WNT target gene glutamine synthetase, which synthesises glutamine from ammonia. 
Zone 2 hepatocytes are difficult to define, zone 2 often represents the transitional 
region between the more distinct zone 1 periportal hepatocytes and the perivenular 
zone 3 hepatocytes, although single cell ribonucleic acid (RNA) sequencing (RNA-
Seq) is beginning to reveal unique properties of the zone 2 hepatocytes11. All 
hepatocytes express albumin and can also synthesise serum proteins such as 
transthyretin and the transferrin transporters12.   
 
Figure 1.1 – Liver anatomy  
 
Figure 1.1: Basic illustration of liver structure. a. Liver macroanatomy b. Liver 
microanatomy, the liver has multiple lobes, permeated by two vascular networks; the 
hepatic artery and portal vein accompanied with the bile ducts form a branching 
network labelled the portal tract (PT); the central vein (CV) forms an opposing 
vascular network. Situated between the two vascular networks is the hepatocyte 
epithelium. c. Blood flows from the PT to the CV along the liver sinusoids. Bile flows 
in an opposite direction through the canaliculi to the bile ducts at the PT. There are 3 
zones of hepatocytes, Zone 1 begins at the PT progressing to zone 2 and zone 3, around 
the CV. 
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Remarkably, the liver can regenerate after acute injury or resection resulting in an 
organised and regulated expansion of the remaining tissue. This is achieved through 
cell division to compensate for lost tissue and return to normal liver function. 
However, severe and repetitive, chronic, injury to the liver causes liver disease, leading 
to gross alterations in liver architecture and function, eventually more systemic 
complications develop such as acites, bleeding varices, jaundice and hepatic 
encephalopathy. Liver disease eventually causes liver cirrhosis, which is fatal and can 
cause organ failure or develop into hepatocellular carcinoma, for which the only 
treatment at this stage in the disease is organ transplant. 
 
Liver Disease 
Epidemiology and aetiology 
Liver disease is a growing burden to healthcare providers worldwide13,14. Increased 
incidence and the prevalence of liver disease are linked to areas with endemic: viral 
hepatitis infections, excessive alcohol consumption and obesity15–20.  
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the primary cause 
of chronic liver disease in Asia and Africa, with a lower prevalence in economically 
developed, western countries. Liver disease arises from HBV and HCV interactions 
with the host immune system, which over time, results in chronic inflammation and 
fibrosis19,20. HCV combined with human immunodeficiency virus further increase the 
risk of developing liver disease21. Other viral hepatitis infections involve the 
enterically transmitted HAV and HEV viruses and the unusual, defective RNA virus 
HDV, which can only infect humans in the presence of HBV or the HBV surface 
antigen, HBsAg22. HAV and HEV infection causes acute liver injury that rarely 
progresses to chronic disease23.  
Chronic alcohol abuse and subsequent liver disease is a growing problem for 
economically developed nations in Europe, the United States of America and parts of 
Asia17. The pathological mechanism of alcohol related liver disease can be linked to 
ethanol metabolism, which contributes to disease through disruption to fatty acid 
oxidation, promoting steatosis24. The loss of gut epithelial integrity caused by excess 
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alcohol can also induce liver disease as it enables the translocation of 
lipopolysaccharides (LPS) to the liver, where it stimulates inflammation and excessive 
TNFα activation, leading to hepatitis16. 
Non-alcoholic fatty liver disease is prevalent in obese people and is more likely in 
diabetic patients with insulin resistance and individuals that have metabolic 
syndrome25. Accumulation of lipids in hepatocytes cause organelle and cytoskeletal 
damage, which results in cell ballooning and necrosis, triggering inflammation, 
fibrosis and eventual cirrhosis26.   
Other causes of liver diseases include autoimmune disorders27, and iron overload 
disorders, caused by a genetic defect or a secondary consequence of another 
pathology28. The cholangiopathies are diseases that predominantly affect the BECs in 
the bile ducts. They include the idiopathic primary biliary cirrhosis, the autoimmune 
or infection induced sclerosing cholangitis, biliary cysts and the biliary cancer, 
cholangiocarcinoma29–31. 
Whether liver disease is caused by infection, toxic insult or autoimmunity, the different 
factors and disorders that induce disease feed in to common processes associated with 
injury response. Ultimately, they cause necrosis/apoptosis, chronic inflammation, 
irreversible fibrosis, complete loss of organ function and destruction of the tissue 
epithelia32 (Figure 1.2). 
 
Hepatocytes in diseased livers have a defective regenerative capacity  
The progression of liver disease and cirrhosis can be determined through histological 
scoring of liver fibrosis and inflammation along with clinical observations that are 
combined with the Child-Pugh criteria; which scores the severity of the patient’s liver 
disease according to the severity of their symptoms. Pathological studies have utilised 
these scoring systems to measure parenchymal cell cycle arrest and senescence in 
relation to liver disease severity. These studies identified that markers of cell cycle 
arrest and senescence increase with disease severity33–36, implying that hepatocyte 
regeneration becomes impaired as chronic liver disease develops.  
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Alongside the progression of disease severity and impaired hepatocyte regeneration is 
the formation of a ductular reaction (DR)37–39. It is hypothesised that cells in the DR 
can act as hepatic progenitor cells (HPC), providing an alternative source for liver 
regeneration, and therefore compensating for defective hepatocyte regeneration40–42 
(Figure 1.2).  
 
Figure 1.2 – Development of liver disease  
 
Figure 1.2: Simplified diagram presenting the progression of chronic liver disease 
from injury to inflammation, fibrosis and eventual liver cirrhosis. Repetitive liver 
injury caused by toxic insult, high fat diet or viral infection triggers; inflammation and 
leucocyte recruitment, stellate cell activation to myofibroblasts, fibrosis, disruption of 
tissue architecture and ductular reaction (DR). The number of senescent hepatocytes 
also increases.  
 
The ductular reaction 
Ductular reactions are thought to originate from the canal of herings, a structure 
located between the PT and parenchyma (Figure 1.1) where there is contact between 
BECs and hepatocytes41,43.  At this interface between the biliary and hepatocyte 
epithelia, it has been proposed that a bipotent HPC exists38,44,45, differentiating to either 
a BEC or hepatocyte cell fate. Although DR are heterogenous43, they can be broadly 
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described as an expansion and infiltration of biliary duct like cells in to the 
parenchyma.  
The DR is not solely comprised from epithelial cells; macrophages and activated 
stellate cells also have an important role in regulating the DR46,47 via a diverse range 
of signalling pathways. Infiltrating macrophages regulate DR expansion and cell fate 
through multiple signalling molecules such as TNFα, TWEAK, IL6, OSM and WNT 
48–52. The stromal, hepatic stellate cell (HSC), has an important role in the formation 
of the DR53, and induces DR expansion via FGF7 secretion54. Notch mediated cross 
talk between activated HSCs, myofibroblasts, and BECs promotes BEC proliferation 
and maintains a biliary phenotype in the DR52,55–57. The DR niche also involves a 
specialised extracellular matrix (ECM)46,58 that regulates the migration and expansion 
of the DR through various adhesion molecules such as galectin-359, NCAM60 and 
integrins αvβ5 and αvβ355.  
The DR can have pathological consequences in the liver as it is closely linked with 
fibrosis42,61–63. The primary cell responsible for the fibrotic phenotype in the liver is 
the ECM producing HSC64. Hepatocyte damage activates HSCs65–67, resulting in 
cytokine secretion and leucocyte recruitment32. It has been shown that HSC derived 
fibrosis may have a limited, pro-survival, benefit after liver injury68. However, chronic 
injury results in overactivation of the HSC population resulting in excessive fibrosis69 
and a poor clinical outcome36. It is therefore possible that DRs, containing activated 
HSCs, can have both beneficial and adverse consequences, dependent upon the 
duration and type of liver injury. Continuous liver injury, resulting in repetitive 
stimulation of the DR could imbalance the HSC/myofibroblast population, promoting 
fibrosis instead of regeneration.  
To verify the bipotential regenerative capacity of the DR and clonally link cells from 
the DR with neighbouring hepatocytes a seminal study by Lin et al used mutations in 
human mitochondrial deoxyribonucleic acid (DNA) to trace the clonality between the 
DR and hepatocytes in human tissue70. Mutations in the exclusive mitochondrial gene, 
cytochrome C oxidase (CCO), enabled immuno-histochemical tracing of CCO 
deficient cells. The clonality of the CCO deficient cells was then verified using laser 
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capture microdissection. Using this technique Lin et al confirmed that hepatocytes and 
BECs in the DR shared a common cell of origin in the adult human.  
Although comprehensive liver pathology studies have clonally linked DR with 
hepatocytes45,70–72, they do not definitively prove that a biliary derived ductal HPC 
regenerates the hepatocyte epithelium. Ductal metaplasia of hepatocytes can also occur 
in diseased livers73,74, contributing hepatocyte derived epithelial cells to the DR. 
Generally, metaplastic hepatocytes do not convert completely to a BEC fate but they 
do share cell markers and the same cell morphology with the biliary ductules75. 
Therefore, clonal tracing of human cells reveal an ancestral link between the two 
epithelial populations but do not reveal the direction of cell fate: hepatocyte to BEC or 
BEC to hepatocyte.  
 
Organ failure and potential treatments 
Treatment of liver disease is determined by the severity of organ failure, the degree of 
fibrosis and the advancement of liver cirrhosis. Primarily, treatment focuses on 
removing the underlying causes of disease. However, once liver cirrhosis is 
established, patient treatment also focuses on maintaining liver function through 
careful modulation of the diet, increasing protein intake and addressing features that 
cause cirrhotic decompensation76.  
For cirrhotic patients or patients with liver cancer the only curative treatment available 
is liver transplant. A major limitation with liver organ transplant is the limited number 
of donors, which does not match the growing demand of recipient patients. Another 
issue associated with organ transplant is the need for life long immune suppressants to 
avoid host rejection of the transplanted organ77.   
Cell transplantation therapies have been proposed as an alternative treatment to whole 
organ transplant78. This approach could solve the issue arising from donor liver 
shortages and immune compatibility, depending on the source of the transplanted 
cells78. Both mouse and human adult hepatocytes can repopulate livers that have the 
genetic metabolic disorder, hereditary tyrosinaemia type I, caused by mutations in the 
fumarylacetoacetate hydrolase (Fah) gene79,80. The FAH-/- mouse can survive when 
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supplemented with 2-(2-nitro-4-trifluoro-methylbenzyol)-1,3-cyclohexanedione 
(NTBC) which prevents the accumulation of metabolically derived hepatotoxins in the 
hepatocytes81. Removal of NTBC treatment from the FAH-/- mouse followed by 
transplantation of FAH+/+ hepatocytes creates a competitive environment suitable for 
hepatocyte engraftment79,80. However, the availability of clinical grade primary adult 
hepatocytes would not be adequate as they cannot be expanded in vitro and they would 
also require the use of immune-suppressants.  A solution to this problem would be the 
use of pluripotent stem cells: either  embryonic stem cells (ESC)82 or induced 
pluripotent stem cells (iPSC)83 to acquire an unlimited amount of hepatocytes. iPSC 
derived hepatocytes could be generated from the patient’s fibroblasts allowing for an 
autograft transplant, avoiding potential complications from host immune rejection. 
However, one enduring risk with ESC and iPSC based therapies is ensuring that 
transplanted cells are safe and fully differentiated, to prevent teratoma and aberrant 
tissue formation78.  
Another, potentially, therapeutic cell would be an expandable HPC. HPCs can be 
isolated using the HPC markers: CD24, EpCAM, CD133, Sca1 and Lgr584–88. Isolated 
HPCs from mouse and human have been cultured in organoids or a 2 dimensional 
monolayer and successfully transplanted into injured mouse livers86,87,89. Another 
source for HPCs has recently been developed, which chemically induces primary adult 
mouse and rat hepatocytes to convert to a bipotent hepatic progenitor90. Using small 
molecules to inhibit Rho-associated kinase type 1, transforming growth factor-β 
receptor and glycogen synthase kinase-3 in hepatocytes, Katsuda et al discovered a 
bipotent progenitor that can be successfully expanded in vitro and transplanted in to 
recipient mouse livers90. Technically, the chemically induced HPC method has not 
been applied to human hepatocytes, it is unknown how effective the chemical cocktail 
is at converting human hepatocytes to HPCs. Huch et al has shown that tissue culture 
methods need to be optimised when changing from mouse to human HPCs89, therefore 
further characterisation and optimisation is needed to translate this technology to the 
clinic.  
A different, less invasive, approach to cell transplant could be through stimulation of 
endogenous liver cells to induce liver regeneration. Recently, Rezvani et al showed 
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that abundant myofibroblasts, generated during liver injury, could be re-programmed 
in vivo to an hepatocyte fate with non-integrating viral vectors that express key 
transcription factors91. Although this experiment revealed an attractive, new, source of 
regeneration in the liver; there are some significant questions that need to be addressed 
before it could be applied clinically. Firstly, can the low reprograming efficiency, less 
than 1%, be improved? Secondly, will the re-programmed hepatocytes maintain a 
healthy hepatocyte phenotype over a prolonged period? Lastly, can the reprogramming 
system be controlled sufficiently to ensure there are no off-target effects, or, avoid any 
abnormal, detrimental, impacts on the resident myofibroblast population? 
The resident HPC in the DR is a more obvious endogenous cell population that could 
be targeted to enhance regeneration in the cirrhotic patient. This approach is dependent 
on a complete understanding of the regulatory pathways that control the DR and HPC 
fate. To enable the discovery of these regulatory pathways we would need suitable 
animal models that recapitulate human disease and allow us to study HPC derived 
regeneration. A therapeutic approach that focuses on DR modulation to promote HPC 
derived regeneration, would also need to avoid the harmful fibrosis that occurs in 
parallel with the DR. This may be possible, as a recent paper by Gieseck III et al 
showed that supressing HSC fibrosis via specific deletion of part of the IL13 signalling 
receptor does not influence BEC expansion92. Providing evidence that the DR does not 
require a, fibrotic, HSC to expand the potentially regenerative BEC component of the 
DR.  
To summarise, there is a need for alternative therapies to relieve demand on liver organ 
donations. Cell therapies are currently the obvious choice if a suitable, clinical grade, 
and expandable cellular source can be identified. There are also potential risk factors 
such as: immune-rejection, failure to engraft correctly, and maintenance of a functional 
liver phenotype that will also need to be addressed. Another, potential therapeutic 
approach would be to stimulate endogenous regeneration through careful modulation 
of the DR. This would depend upon a robust understanding of the underlying biology 
that regulates the DR and what determines HPC fate in vivo. One could also foresee a 
future clinical treatment programme that both transplants pro-regenerative cells and 
uses small molecules to also enhance endogenous cell regeneration.  
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Liver regeneration 
Adult tissue regeneration  
Tissue regeneration is a process of regrowth, to maintain tissue homeostasis and 
replace lost or damaged tissue after an injurious event. The ability to regenerate varies 
between species; some organisms, such as the flatworm planaria have an extraordinary 
capacity to regenerate every part of their body93; salamanders can regenerate whole 
limbs94; while mammals, such as the mouse can regenerate a limited number of tissues, 
for example the  intestinal epithelium, which is replaced every 3-5days95. Strikingly, 
there are common features and signals that repeatedly occur in different regenerative 
scenarios between the various species93,96.  Developmental morphogens and signals 
such as WNT93,97–99, hedgehog (HH)100,101 and notch102,103 are commonly detected in 
sites of regeneration along with stromal104,105, vascular106,107 and immune cells52,108,109, 
and a specialized basement membrane110,111, that all have a role in forming the 
regenerative niche. Although, their function in a particular niche can be different 
between separate tissues and organs112. Broadly, one could describe a general, 
successful, regenerative response after injury as a sequence of: damage detection, 
inflammation113, changes to the tissue microenvironment that stimulate activation of a 
tissue resident stem cell114–116 or re-programming of a committed somatic cell into a 
regenerative cell117,118, differentiation, replacement of lost tissue, and resolution of 
inflammation (Figure 1.3). 
However, tissue regeneration is not that simple, it is a complex, highly orchestrated, 
event, which can be disrupted by the duration and severity of the injury113 along with 
aging119. Indeed, aging has a detrimental effect on regeneration, aged organisms cannot 
regenerate as effectively as their younger counterparts120–122. Interestingly, exposure 
of an aged tissue to a young systemic environment rejuvenates the aged tissue’s 
regenerative capacity123. Another process involving time, the circadian rhythm, can 
also influence the regenerative response in some tissues, such as the liver124,125.   
Although mammalian regeneration is relatively restricted when compared to other 
vertebrate and invertebrate species, for example mammals cannot regrow limbs, some 
tissues can regenerate after injury. One mammalian organ that is capable of 
regeneration after toxic injury and resection is the liver126.  
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Figure 1.3 – Standard epithelial regenerative response  
 
Figure 1.3: Common features observed during epithelial damage and regeneration: 
cell death/damage (apoptosis/necrosis/senescence), inflammation via DAMPs PAMPs 
and SASP secretion, leucocyte recruitment, clearance (phagocytosis), ECM 
remodelling/fibrosis, and signalling to stimulate tissue resident stem cells or induce 
epithelial division. DAMPs = damage associated molecular patterns, PAMPs =  
pathogen associated molecular patterns, SASP= senescence associated secretory 
phenotype.  
 
Hepatocyte mediated regeneration 
Under homeostatic conditions, hepatocyte turnover is relatively slow127 when 
compared to other epithelia such as the epidermis and intestine95,128. However, the liver 
can undergo rapid growth or re-growth when required. Liver resection or toxic insult 
stimulates hepatocyte division, this process is regulated by: systemic and local 
signalling factors, circulating blood flow, ECM changes and cell to cell interactions126.  
Liver resection by partial hepatectomy has been the major model used to study 
hepatocyte regeneration. Immediately after resection changes to portal blood pressure 
stimulate hepatocyte growth factor (HGF) secretion from the sinusoidal endothelium 
and HSCs, which induces hepatocyte division129. Additional, secreted cytokines and 
growth factors that regulate hepatocyte growth include: epidermal growth factor 
(EGF), transforming growth factor-α (TGFα), interleukin 6 (IL6) and fibroblast 
growth factors (FGFs)129. It has been suggested that many of these signalling axes are 
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redundant, allowing for alternative pro-proliferation signals to prevent hepatocyte 
regenerative failure126. Hepatocyte hypertrophy also occurs during liver regeneration, 
proceeding cell division or acting solely to regenerate the liver after mild, 30%, partial 
hepatectomy130. Another hepatocyte feature that increases during regeneration is 
changes to cell ploidy levels. The number of polyploidy hepatocytes increases, 
whether this is a cyto-protective mechanism, pro-regenerative mechanism, or a 
response to changes in metabolism is unclear131. 
Hepatocytes have an important metabolic role in the body; disruption of liver 
metabolism, influences liver regeneration. After liver resection or toxic injury 
circulating metabolic products become altered. For example, serum glucose decreases, 
interestingly, glucose supplements after liver injury have a negative outcome on liver 
regeneration, and reducing the supply of insulin to the liver impairs growth129, 
suggesting that changes to metabolism influence the regenerative response in the 
liver132.  Additionally, amino acid and long chain fatty acid supplements enhance 
hepatocyte DNA synthesis, improving liver regeneration129.   
Liver organ size is dependent on organism size. When a liver is transplanted to a larger 
host, the organ grows to compensate for this change, increasing in volume133,134. Also, 
rat parabios experiments have shown that liver resection in one organism results in 
liver growth of both the resected liver and the, connected, neighbouring one126. Both 
these findings highlight the importance of systemic factors on regulating liver size and 
proliferation. 
Other factors that influence the hepatostat (hepatocyte rheostat) include signals that 
terminate hepatocyte proliferation such as: TGFβ, ILK, glypican3 and the hippo 
signalling pathway. Peri-cellular TGFβ inhibits hepatocyte proliferation and blocking 
the TGFβ receptor induces hepatocyte proliferation135. Deletion of hepatocyte integrin 
linked kinase (ILK) results in a failure to terminate liver growth after partial 
hepatectomy136,137. Ablation or knockdown of the ECM protein glypican3 causes 
hepatomegaly and increased  hepatocyte proliferation138,139. Finally, overactivation of 
the hippo pathway, via expression of phosphorylation resistant yes associated protein 
(YAP) in hepatocytes, results in uncontrolled hepatocyte expansion, hepatomegaly and 
eventual tumorigenesis140,141. Regulation of the Hippo pathway, potentially through 
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the ECM receptors, the integrins, and ILK, or mechanotransduction142, adds another 
dimension to the regulation of liver size that may be controlled by physical properties 
as well as chemical ones.  
In summary, both local and systemic factors regulate liver growth and hepatocyte 
proliferation. Maintenance of the correct liver size is vital and regulated by multiple 
processes.  The hepatocyte epithelium can regenerate rapidly (with in 48hours) after 
an injurious event to replace lost tissue and return to pre-injury liver size.  
 
A liver stem cell and hepatic progenitor cell theory: contradictions and 
uncertainty 
Investigations, searching for a liver stem cell have produced contradictory results, 
generating multiple, inconclusive, theories143. Unlike some organs, such as skeletal 
muscle144,145 and hair follicles146, there is not an easily recognisable stem cell 
compartment in the liver. Cells in the biliary ductules at the canal of herrings are the 
principal HPC/liver stem cell candidate43, however, various mouse lineage tracing 
experiments contradict this theory.  
Original HPC lineage tracing experiments used BEC genes such as Sox9 (SRY (sex 
determining region Y)-box 9),  Opn (osteopontin), Hnf1b (hepatocyte nuclear factor 
1-β) and K19 (cytokeratin 19) to regulate inducible reporters and trace HPC mediated 
regeneration in vivo147–150. A problem with some of these genes is that injured 
hepatocytes also express them, which causes non-specific labelling151,152. A key 
example is the inducible Sox9CreERT transgene, first used to lineage trace BEC and HPC 
in vivo, resulting in labelled hepatocytes thought to derive from a prelabelled HPC148. 
However, a subsequent study, using a different Sox9CreERT transgene, did not re-
produce the same result showing no HPC contribution to the hepatocyte epithelium153. 
The contradictory results could be explained by experiments that revealed hepatocytes 
express biliary markers such as SOX9 and OPN during injury151,152. Other HPC 
markers, Foxl1154,155, Lgr586, are only expressed during liver injury and can be 
expressed in both hepatocytes and BEC making it difficult to determine the origin of 
the HPC. Although,  ablation of Foxl1 positive HPC, via a diphtheria toxin receptor 
transgene, impairs liver regeneration155.  As for the HPC lineage tracing models that 
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are biliary specific, Hnf1bCreERT and K19CreERT, only a small fraction, less than 2%, of 
hepatocytes are regenerated by HPCs150,156 when injured with commonly used mouse 
liver injury models such as: diethyl-1,4-dihydro-2,4,6-trimethyl-pyridine-3,5-
dicarboxylate (DDC) diet and choline-deficient diet with ethionine (CDE) diet.   
An alternative approach to detect HPC mediated regeneration of the hepatocyte 
epithelium used hepatotropic viral Cre or AlbCreERT/DreERT transgenes to completely 
label the hepatocyte epithelium156–161, over 99% of hepatocytes were labelled with a 
heritable marker. The experimental hypothesis proposed that a non-hepatocyte source 
of regeneration, such as the HPC, would cause a reduction in the number of labelled 
hepatocytes after liver injury. Again, a range of commonly used toxic liver injury 
models and liver resection failed to reduce the number of labelled hepatocytes, 
indicating that regeneration occurred through hepatocyte self-duplication and not from 
a HPC source. Although, in human chronic liver disease hepatocyte regeneration is 
impaired via cellular senescence and expression of p21, therefore, it is questionable 
whether the mouse liver injury models that were used, primarily CDE and DDC, are 
suitable for studying HPC derived regeneration. 
Solely focusing on the hepatocyte compartment, two cell populations have been 
identified as potential hepatocyte progenitors. Under homeostatic conditions, zone3, 
Axin2 positive hepatocytes around the central vein were shown to clonally expand in 
to the parenchyma127. Axin2 negatively regulates β-Catenin162, an effector of the 
canonical Wnt signalling pathway, which induces hepatocyte proliferation9. The 
Axin2CreERT transgene, which was inserted in to the endogenous Axin2 locus163 and 
utilised by Wang et al to lineage trace CV hepatocytes was heterozygous. Although 
heterozygous deletions of Axin2 has been shown not to disrupt Wnt signalling during 
a short, 70 hour, in vitro experiment using primary osteoprogenitors164, it is unknown 
how mutating one Axin2 gene in hepatocytes influences liver Wnt signalling, and 
therefore hepatocyte proliferation, over the lifetime of the mouse. The CV progenitor 
cell theory was also supported by partial hepatectomy experiments in neonatal mice165, 
although, the phenotype is lost as the neonates mature into adults. 
In contrast, predominant Zone3 hepatocyte damage, caused by the hepatotoxin carbon 
tetrachloride (CCL4), results in regeneration from a periportal Sox9 positive 
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hepatocyte166. Furthermore, label retaining experiments167 and periportal (zone1) 
Mfsd2a positive hepatocyte lineage tracing168 also support the theory that hepatocyte 
regeneration originates periportally. Opposing the idea that there is a spatially defined 
hepatocyte progenitor, multiple hepatocyte lineage tracing experiments have revealed 
that there is no zonal bias to hepatocyte regeneration9,169.  
In summary, mouse lineage tracing of HPCs, which express BEC markers, have 
produced inconsistent results. Further to this, mouse lineage tracing models that label 
the entire hepatocyte epithelium have revealed that hepatocytes only regenerate via 
self-duplication, detecting a negligible contribution from a HPC. Uncertainty persists 
as to whether hepatocyte self-duplication is a stochastic process or spatially restricted 
to multiple pro-regenerative populations that have been identified in the hepatocyte 
epithelium. Finally, questions remain; if a HPC expressing BEC markers cannot 
regenerate hepatocytes, is this representative of the biology seen in humans? Or, is it 
an experimental artefact produced by mouse liver injury models that do not 
recapitulate the impaired hepatocyte regeneration seen in human chronic liver disease? 
 
Animal models of liver disease and hepatic progenitor mediated 
regeneration  
Rat models  
Rats were the first model organism employed to study HPCs, or oval cells as they are 
known in the rat due to their unique morphology.  To induce a DR, and oval cell 
regeneration, rats were treated with 2-acetylaminofluorene (AAF), which inhibits 
hepatocyte proliferation170, followed by partial hepatectomy (PH), to stimulate liver 
regeneration171. Histological analysis of the regenerating rat livers identified oval cells 
emerging from biliary ductules44 and resulted in proliferating periportal 
hepatocytes172. An oval cell response could also be generated by AAF combined with 
different  hepatotoxins, CCL4 and allyl alcohol173. The key factor in mediating an oval 
cell response in the rat was the inclusion of AAF, to inhibit hepatocyte proliferation 
and impair hepatocyte mediated regeneration.  
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Mouse models  
To utilise the growing availability of mouse transgenic tools and to use a more tractable 
mammalian model organism researchers began to use mice to study liver regeneration. 
AAF is not metabolised by mouse hepatocytes174 and therefore does not induce cell 
cycle arrest. As an alternative to the AAF-PH injury model, DDC diet and CDE diet 
were used to study HPCs as they induced a DR and cells that shared some 
morphological similarities with oval cells52,143. However, DDC and CDE toxic injury 
diets do not inhibit hepatocyte proliferation155,156; a potential explanation as to why 
they do not induce significant HPC mediated regeneration of hepatocytes in the mouse 
liver150,156,159.  
Recent genetic based models of liver injury have provided evidence that a biliary 
derived HPC could regenerate hepatocytes in the mouse. Using Cre-Loxp to mutate 
Mdm2 specifically in mouse hepatocytes, Lu et al showed an accumulation of p53 and 
subsequent p21 expression in hepatocytes87. In this setting of impaired hepatocyte 
regeneration, a DR emerged along with healthy periportal hepatocytes, reproducing 
histological features seen in rat and human HPC studies. Lu et al also transplanted 
biliary derived, labelled, HPC in to the MDM2 KO liver and showed HPC to 
hepatocyte differentiation; replicating data generated by Huch et al, who also 
transplanted HPCs in to a liver injury model where hepatocyte survival is impaired86,89. 
Huch et al isolated Wnt responsive Lgr5 positive cells from liver injured by CCL4 
intoxication. These Lgr5 positive HPCs formed organoids when cultured in matrigel 
and displayed a bipotent phenotype; when transplanted into FAH-/- mice, both human 
and mouse HPCs engrafted and formed mature, functional, hepatocytes86,89. Other 
genetic injury models that disrupted hepatocyte proliferation via  Dnmt1 or Birc5 
mutations, induced DNA damage and hepatocyte senescence, which resulted in a DR 
and HPC response, followed by liver recovery175,176. 
 
Zebrafish models  
Experiments in the non-mammalian, vertebrate model organism Danio rerio (the 
zebrafish) have also produced evidence that cells in the biliary epithelium can 
regenerate hepatocytes. These experiments utilised the bacterial gene encoding 
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nitroreductase (Ntr), which metabolically converts the harmless prodrug 
metronidazole in to a cytotoxic compound177. By placing ntr expression under the 
regulation of a hepatocyte specific promoter, fabp10a or ifabp, the hepatocyte 
compartment could be ablated by metronidazole administration. Extensive loss of the 
hepatocyte compartment resulted in a Notch, Wnt and BMP mediated BEC expansion 
and conversion into hepatocytes178–180.  
 
To conclude, animal liver injury models that excessively ablate hepatocytes or inhibit 
hepatocyte proliferation, induce a HPC response in the form of a DR, which is 
followed by hepatocyte regeneration. Mouse liver injury models, originally used for 
HPC lineage tracing, induce a DR but do not impair hepatocyte proliferation. To 
determine if a biliary derived HPC can differentiate in to hepatocytes in the mouse, a 
liver injury model that impairs the hepatocyte regenerative capacity is required. 
 
Cell fate and differentiation in the liver 
The lack of a robust mammalian in vivo model to lineage trace HPCs during 
regeneration has hindered the discovery of cell processes and signalling pathways that 
regulate HPC fate during adult liver injury and regeneration. However, much is known 
from developmental studies and hepatocyte lineage tracing experiments.  
 
Development 
The two liver epithelia (hepatocytes and BECs) originate from the endoderm lineage 
during embryonic development. A sequence of cell specification events; involving 
formation of the definitive endoderm followed by the development of foregut 
endoderm, results in the generation of the liver diverticulum via mesenchymal bone 
morphogenetic protein 4 (BMP4) and FGF signalling181. The liver diverticulum buds 
out ventrally from the foregut, it is in this liver bud where the hepatic endoderm 
differentiates in to the hepatoblast, the hepatocyte and BEC progenitor, and liver 
organogenesis occurs5. In the liver bud, Hex positive hepatoblasts transform from a 
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columnar to a pseudostratified epithelium  followed by delamination and migration in 
to the septum transversum mesenchyme (STM)182, where hepatoblast differentiation 
is induced183. Endothelial cells also regulate liver organogenesis, deletion of VEGFR2 
causes a loss of endothelial cells during hepatic development, which inhibits liver bud 
and hepatoblast formation184. 
During hepatic development, there are key regulatory transcription factors that control 
chromatin organisation and gene expression in the hepatic progenitors, determining 
cell fate185. Transcriptional hierarchy in the developing hepatic endoderm begins with 
the expression of forkhead box protein-A1/2 (FOXA1/2), GATA binding protein-4/6 
(GATA4/6) and hepatocyte nuclear factor-vHNF1 (HNF1β) transcription factors, 
which are essential for hepatic induction186–190. Importantly, FOXA1/2 are pioneer 
transcription factors191 that remodel chromatin to expose hepatic genes, enabling 
progenitor differentiation186,192. Further specification of the hepatic endoderm, results 
in the expression of the Hex homeobox transcription factor (Hhex), which is also 
essential for liver bud formation182.  Later, as the hepatic progenitors progress to the 
hepatoblast stage, hepatocyte nuclear factors 4α, 1β and 6 (HNF4α, HNF1β and 
HNFF6) are expressed193,194, regulating hepatoblast expansion and migration in to the 
STM. Hepatoblast differentiation is partially regulated by the T-box gene repressor 
TBX3195 and the CCAAT/ enhancer binding protein-α (C/EBPα)196, which repress and 
promote (respectively) biliary transcription factors HNF6 and HNF1β.  
Hepatocytic differentiation and maturation requires Oncostatin M (OSM), HGF, WNT 
and glucorticoids4. Two transcription factors HNF4α and PROX1 are essential in 
hepatocyte specification: HNF4α expression is necessary to develop a mature, 
organised hepatocyte epithelium193,197,198, and PROX1 promotes a hepatocyte fate, 
deletion of Prox1 results in excessive BEC differentiation, aberrant ECM deposition 
and liver hypoplasia199,200.  
Development of the biliary network is dependent on mesenchymal jagged-1/notch 
signalling201–203, a TGFβ-activin signalling gradient204,205 and YAP activation206,207. 
These signalling axes regulate biliary specific transcription factors;  SOX9, SOX4, 
HNF6, HHEX and HNF1β , which are essential for biliary development and 
morphogenesis196,208–212. 
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Canonical and non-canonical WNT signalling pathways have distinct functions at 
various stages in hepatic development. β-Catenin, a target of canonical Wnt signalling 
is essential for maintaining the endoderm lineage213. However, modulated WNT 
signalling is needed to pattern the anterior and posterior endoderm, secretion of   Sfrp5 
a negative regulator of WNT ensures foregut development prior to formation of the 
liver diverticulum, supressing the canonical and non-canonical functions of Wnt11214. 
In the zebrafish, mesodermal derived Wnt2b has been identified as an important signal 
in liver specification and hepatoblast formation215 targeting the EpCAM positive 
hepatic endoderm216. At later stages of development, when the hepatoblasts have 
migrated in to the STM, sinusoidal endothelial cells secrete Wnt9a to induce β-
Catenin, which drives hepatoblast proliferation and maturation217,218. Another Wnt 
ligand, Wnt5a, suppresses hepatoblast to biliary differentiation219, further to this 
deletion of β-Catenin does not influence biliary development220, suggesting canonical 
WNT signalling primarily influences hepatoblast to  hepatocyte differentiation at the 
late stages of liver development. 
In conclusion, hepatic development is dependent upon the expression of pioneer 
transcription factors that modulate chromatin structure and enable hepatic gene 
expression. Signals from mesenchymal and endothelial cells are essential for cell fate 
specification and subsequent tissue organisation. Many of the signals present in 
development are also present in the injured and regenerating adult liver.  
 
In vitro studies 
Isolation of hepatic progenitors and differentiation of ESC in vitro have also identified 
essential factors needed to promote hepatic differentiation. Isolated mouse hepatic 
progenitors from stage E13.5 embryos when supplemented with HGF and OSM 
upregulate C/EBPα221, a factor that promotes hepatocytic differentiation. In the same 
isolated progenitors196, ECM components, laminin and type I/IV collagen, suppressed 
C/EBPβ221, a pro-biliary differentiation transcription factor205. Human ESC 
differentiation requires WNT3a and activin A to form hepatic endoderm222. Further 
maturation of hepatic endoderm to hepatoblast and hepatocytes requires: retinoic acid, 
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FGF10, FGF4, HGF, OSM, DMSO, insulin223,224, and recombinant laminins (LN521 
and LN111)225.  
Comparisons between isolated neonatal and adult HPC have revealed an epigenetic 
mechanism that restricts adult HPC differentiation to hepatocytes. Repression of the 
micro RNA Mir122 via the BEC specific transcription factor grainy head-like 2 
(GRHL2) prevents adult HPC differentiation. In contrast, expression of Mir122 in 
neonatal HPCs enhances hepatocytic differentiation226,227. Differentiation of adult 
HPC organoids is possible when TGFβ and Notch signalling is inhibited, cell growth 
is reduced, and media is supplemented with BMP7, FGF19 and dexamethasone86,89. 
Although in vitro assays do not completely encompass and recapitulate the biology 
controlling cell fate in vivo. They do reveal important candidate ligands and signalling 
axes that should be investigated in vivo to understand how the identified signals 
integrate with liver regeneration.  
 
In vivo studies 
Investigations of factors that affect HPC derived regeneration have been hampered by 
the lack of an appropriate mouse model. However, work by Boulter et al revealed 
parallels between signalling in liver development and adult regeneration. Boulter et al, 
showed, similar to development,  WNT signalling induced hepatocytic differentiation 
and Notch signalling induced BEC differentiation52. Although the source of the WNT 
in adult regeneration was macrophage derived and not endothelial or mesenchymal. 
The ECM has also been proposed to influence HPC fate, Español-Suñer et al used a 
pharmaceutical analogue of prostacyclin, iloprost, to indirectly suppress laminin 
expression in vivo. This resulted in an increase in the amount of OPNCreERT labelled 
hepatocytes ostensibly derived from a biliary DR origin149. Although, it has been 
previously mentioned that OPN can be expressed by damaged, periportal, 
hepatocytes152 and therefore the origin of these hepatocytes is not certain. Also, 
iloprost does not solely influence laminin expression, it has many off-target effects 
and can suppress HPC proliferation172. Laminin is a key constituent of the BEC and 
HPC niche44,46,228, more targeted experiments are needed to evaluate the role of 
laminin loss on cell fate.    
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Overactivation of the canonical notch pathway, via activation of a transgene that 
encodes the Notch intra-cellular domain in hepatocytes, induces transdifferentiation to 
a BEC fate74,158. This phenomenon can be repeated, if a phosphorylation resistant Yap, 
that localises to the nucleus229, is over-expressed in hepatocytes230. However, 
experiments that induce hepatocyte transdifferentiation through injury and not, 
artificial, transgenes results in an incomplete transdifferentiation that is reversible75. 
Therefore, Notch and Hippo signalling does influence hepatocyte fate but how these 
signalling pathways function in the context of liver injury and regeneration is not clear.  
Artificial manipulation of BECs and any HPC residing in the biliary epithelium did 
not produce striking differences in changes to cells fate56. Jors et al utilised a 
conditional Hnf1βCreERT transgene to specifically target BECs and activate either an 
exon 3 deficient β-Catenin that cannot be negatively regulated, resulting in 
overactivation of the canonical Wnt pathway; or ablate Rbpj, a downstream target of 
the canonical notch signalling pathway, loss of which results in impaired notch 
signalling. The rational for this experiment was that if loss of notch signalling and 
activation of Wnt signalling directs HPCs towards a hepatocyte fate, as previously 
hypothesised by Boulter et al52,  then artificial manipulation of these pathways would 
promote HPC differentiation. However, Jors et al did not detect HPC differentiation 
using this model, suggesting other signalling mechanisms may influence HPC to 
hepatocyte differentiation.  
 
To conclude, detailed developmental studies have identified signalling axes and 
transcription factors that regulate hepatic cell fate. How these signalling pathways 
influence cell fate during adult liver regeneration have been partially investigated with 
respect to the Notch, Wnt and Hippo signalling pathways. However, further 
characterisation of these pathways, in a reliable HPC model, is needed to fully 
elucidate factors that regulate HPC differentiation to a hepatocyte fate. Also, little is 
known about the transcription factors that regulate cell fate during adult liver 
regeneration and if there are any, pioneer or master, transcription factors involved. 
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β1-Integrin and liver regeneration  
Extracellular matrix and cell adhesion  
The ECM is an organised structure, composed from protein and saccharide 
macromolecules, arranged in a way that provides structural support for cells and 
facilitates cell migration in all metazoans. For each tissue, the ECM structure and 
composition is different and can undergo dynamic changes in response to distinct 
biological processes such as regeneration, development and tissue damage231. There 
are approximately 300 identified mammalian ECM proteins, which can be classified 
as either collagens, glycoproteins and proteoglycans232. Commonly, ECM forms the 
basement membrane (BM) for all epithelia, key constituents of the BM include: 
collagen, laminin, nidogen and perlecan233–235. The ECM influences cell behaviour by 
stimulating and modulating cell signalling233, determining cell polarity236 and 
regulating stem cell activity111,237. The elasticity of a tissue, determined by the 
composition of the ECM, can also influence cell fate238,239 and promote the progression 
of cancer via integrin activation240. Another feature of the ECM is its ability to bind 
growth factors and other extracellular signalling molecules233. The ECM can modulate 
signals in the cell niche via: activation of latent signalling factors, sequestering factors 
so they cannot interact with the cell, and correctly presenting signalling ligands to cell 
surface receptors233,241. 
The integrins, a major ECM receptor family, facilitate adhesion between the cell and 
the surrounding ECM. Integrin activity is bidirectional, intracellular signals can 
regulate integrin structure and thereby regulate integrin adhesion, conversely integrin 
binding to extracellular ligands can induce intracellular signals to influence cell 
behaviour242. Once an integrin mediated adhesion between the cell and the ECM is 
established an adhesome forms; integrin receptors cluster and recruit components of 
the cytoskeleton, other plasma membrane receptors and adapter proteins243. Integrin 
adhesomes are heterogenous within cells and between different cell types. The 
downstream effects of the adhesome are vast and are still being characterised, they 
have been linked to cytoskeletal rearrangements, facilitating cell migration and 
changes to cell morphology; and inducing signalling cascades resulting in cell survival, 
differentiation and proliferation244. 
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β1-Integrin: an important mutli-functional protein 
The integrin receptor is composed from two subunits, an α-unit and a β-unit that 
heterodimerise to form the complete receptor. There are 8 β-units that can dimerise 
with 18 α-units forming a total of 24 possible receptors242. One integrin subunit, β1-
Integrin, is a major constituent of many integrin receptors. It is also vital to 
embryogenesis, deletion of β1-Integrin is embryonic lethal, resulting in pre-
implantation death245. β1-Integrin heterodimerises with 12 different α-subunits232 and 
is involved in establishing cell polarity246,247, regulating stem cells via BM 
interactions248,249 regulating cancer metastases250,251 and activating growth factor 
signalling axes to promote cell survival and proliferation252,253. Conditional loss of β1-
Integrin generally results in organ hypoplasia, impaired cell growth and defective 
regeneration in many tissues254–257 because it promotes cell survival via ERK-Akt 
activation257,258.   
  
ECM and Integrin expression in the liver 
In the healthy adult mouse and rat liver; type I, III and IV collagen, fibronectin and 
heparan sulfate proteoglycans are broadly distributed throughout the liver, lining the 
sinusoids and forming the ECM at the PT. Laminin and nidogen are also expressed 
throughout the liver, with a higher concentration around the PT259,260, particularly the 
laminin α5 and α1 isoforms261,262. β1-Integrin is widely expressed throughout the liver, 
located in the membrane of both parenchymal (hepatocytes, BEC)259 and non-
parenchymal cells (HSC, Kupffer cells, sinusoid endothelial cells)263. Other integrin 
variants, β6, β4, α6, α3, α2 and αV are expressed in the biliary epithelium; and the α1 
and α5 -integrins are expressed in the liver sinusoids259,264,265. Hepatocytes express 
Itgb1, Itgb5, Itga1, Itga5, Itga9 and Itgav, forming potentially 5 integrin receptors 
capable of binding collagen and the RGD domain found in fibronectins232,266.  
The liver ECM and cell adhesion receptors change during injury260 and as liver disease 
develops an irreversible fibrosis forms267. In human cirrhotic livers, the amount of 
collagen and laminin increases and their distribution changes, resulting in peri-nodular 
ECM deposition and fibrous septa264. Injury induced alterations to the liver ECM 
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increase the stiffness of the tissue268,269, which eventually disrupts liver function and 
promotes liver cancer270  
Integrin expression increases in injured livers271–273 and integrin receptor activity can 
modulate the injury response. During liver injury, αv-Integrin expressed on stromal 
myofibroblasts274 and epithelial cells265 activate latent, extracellular, TGFβ, which 
induces a signalling cascade that promotes ECM secretion. Biliary αvβ5/αvβ3-integrin 
interacts with the matricellular protein CCN1 to induce a biliary derived DR55. 
Hepatocytes require β1-Integrin for growth factor signalling and activation of,  pro-
survival, protein kinase B (Akt)263.  
Although liver fibrosis, caused by excess ECM deposition, eventually has an adverse 
impact on liver function and patient survival, aspects of fibrosis can be beneficial, 
promoting hepatocyte survival68. Increased ECM stiffness also induces hepatocellular 
carcinoma (HCC) proliferation275. Together, this demonstrates the benefits of 
hepatocyte-ECM adhesion for cell survival and growth.  
 
Role of hepatocyte β1-Integrin  
Hepatocyte β1-Integrin augments growth factor signalling, enhancing hepatocyte 
growth and survival. Deletion of β1-Integrin from the hepatocyte epithelium 
suppresses growth factor signalling and proliferation263. Loss of β1-integrin during 
ESC differentiation in vitro resulted in decreased AKT activation and a reduction in 
differentiation276, a probable explanation is that β1-Integrin loss disrupts the essential 
growth factor signals required for hepatic differentiation. Over-expression of ITGB1A 
in immortalised human hepatocytes improved cell survival via activation of MAP 
kinase and apoptosis resistance277. Whether this pro-survival phenotype is caused by 
β1-integrin mediated adhesion alone or is a consequence of increased growth factor 
signalling has not been fully defined. β1-Integrin may also have a role in supporting 
hepatocyte polarity by acting as an intermediate between the ECM and Par1b 
protein278. Furthermore, loss of hepatocyte β1-integrin in vitro disrupts cell 
polarisation and canaliculi formation266. A similar mechanism exists in the  biliary 
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epithelium, where β1-Integrin co-ordinates apical-basal polarity during BEC 
differentiation in development261. 
 
Loss of β1-Integrin from hepatocytes: lessons from cancer and an acute liver 
injury model 
To determine the role of hepatocyte β1-Integrin in disease two investigations used an 
inducible, loss of function, Itgb1 mutation and small interfering RNA (siRNA) to 
suppress Itgb1 expression . In an acute liver injury model (2/3 partial hepatectomy), 
conditional knockout of β1-Integrin mediated by MxCre and floxed Itgb1 resulted in 
decreased EGFR and c-Met activation263. Disruption of hepatocyte growth factor 
signalling during acute liver injury resulted in impaired regeneration, demonstrated by 
a decrease in mouse survival, a decrease in hepatocyte proliferation and an increase in 
parenchymal necrosis. The adverse effect of β1-Integrin loss from hepatocytes was 
investigated further, by inducing liver cancer with oncogenic c-Met and β-Catenin. 
RNAi mediated suppression of  β1-Integrin in hepatocellular carcinoma reduced 
tumour burden and improved mouse survival266. Again, knock down of β1-Integrin 
reduced overactivated growth factor signalling axes present in HCC. Together, these 
investigations demonstrate the role hepatocyte β1-Integrin has in promoting 
proliferation and cell survival, indispensable for successful liver regeneration.  
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Summary 
As one of the rare visceral organs capable of regeneration, the liver has been the focus 
of many investigations into mammalian regeneration. This work has established a 
comprehensive understanding of how the liver regenerates after acute injury and 
resection, along with the discovery of signalling pathways involved with injury 
recognition and inducing division of resident hepatocytes and BECs. However, in 
human chronic liver disease hepatocyte epithelial proliferation is reduced and DR 
appears. Fate tracing of a biliary derived HPC in the DR, using murine lineage tracing 
models, have failed to conclusively determine if a biliary derived DR can significantly 
regenerate the hepatocyte epithelium. Two conclusions can be drawn from this finding: 
one, that biliary derived DRs cannot regenerate hepatocytes and that human liver 
pathology studies were describing hepatocyte ductal-metaplasia; or two, that the 
commonly used mouse liver injury models do not represent human liver disease, 
because the hepatocyte epithelium is still capable of regeneration. To address this 
problem and determine if a biliary derived DR can regenerate the liver I propose the 
following hypothesis.  
 
Hypothesis and aims  
Hypothesis: Impairing hepatocyte regeneration, via ablation of β1-Integrin, will 
induce biliary derived regeneration of the hepatocyte compartment. 
 
I aim to investigate this hypothesis using the following objectives: 
- Establish a highly specific model where hepatocyte β1-Integrin can be ablated 
and concurrent hepatocyte lineage tracing can occur. 
- Develop a biliary lineage tracing model where hepatocyte β1-Integrin 
expression can be targeted independent of a Cre/Loxp transgenic. 
- If an alternative source of hepatocyte regeneration is detected, I will determine 
if any non-hepatocyte derived regeneration results in functional restoration of 
the parenchyma. 
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Liver injury models 
All animal experiments were carried out under procedural guidelines, severity 
protocols and with ethical permission from the University of Edinburgh Animal 
Welfare and Ethical Review Body (AWERB) and the UK Home Office, licence 
number: 70/7847. All animals were housed in a pathogen-free environment and kept 
under standard conditions with a 14-hour day/10-hour night cycle and access to food 
and water ad libitum. 
 
3,5-Diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet 
Supplementation of mouse feed with 3,5-Diethoxycarbonyl-1,4-dihydrocollidine 
(DDC) generates porphyrin in the liver, which results in blockage of the bile ducts and 
liver cholestasis279,280. Consequences of DDC induced cholestasis include portal 
fibrosis, necrosis, inflammation and DR281. 7-10 week old male and female mice were 
given 0.1% DDC mixed with Rat & Mouse No1 Maintenance (RM1) diet (Special Diet 
Services), for 7-10 days.  
 
Methionine and choline deficient (MCD) diet 
The methionine and choline deficient (MCD) diet models non-alcoholic steatohepatitis 
(NASH). The diet’s high fructose and fat content in the absence of methionine and 
choline disrupts mitochondrial β-oxidation and the synthesis of low density lipoprotein 
resulting in steatosis, inflammation, necrosis and fibrosis281. MCD diet (MP 
Biomedicals) was given for 7-14 days to both male and female mice aged 7-10 week 
old. 
 
Thioacetamide (TAA) 
TAA intoxication models liver fibrosis and chronic TAA application generates liver 
cancer282. Liver damage is induced when TAA is metabolised by zone 1 and zone 3 
hepatocytes, generating reactive oxygen species (ROS) that disrupt the cell’s macro-
molecules, triggering cell death281. 7-10 week old male mice were given thioacetamide 
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(TAA) (Sigma Aldrich). TAA was administered in the drinking water at a 
concentration of 300mg/L for 21 days. 
 
Choline deficient ethionine supplemented (CDE) diet 
The Choline deficient ethionine supplemented (CDE) diet disrupts mitochondrial β-
oxidation via choline deficiency and induces liver damage and carcinogenesis via the 
hepatoxin ethionine; CDE diet causes steatosis, inflammation and DR 283. 6 week old 
female mice were first fed a CDE weaning diet for 1 week followed by 4 weeks of 
CDE diet. The weaning diet was choline sufficient, which was followed by the choline 
deficient CDE diet; both were custom made by MP Biomedicals (960412). Mice were 
given normal chow for a 2 week recovery period after CDE diet treatment. 
 
For all hepatotoxic diets, animals that lost more than 20% of their pre-injury body 
weight were taken off injury diet early as they had reached the allowed severity 
threshold according to the project licence approved by the UK Home Office. 
 
Transgenic mouse models 
The animals in this study had a C57BL6/J background and both equal numbers of male 
and female mice were used, unless specified in the text (see CDE diet and TAA 
protocol). 
 
Adeno Associated Virus 8 (AAV8) Cre induction 
Mice between 7-10 weeks of age had Cre mediated recombination induced with 
AAV8.TBG.Pi.Cre.rBG (Penn vector core, CS0644). Control, null, experiments used 
AAV8.TBG.Pi.null.rBG (Penn vector core, CS0255). The adeno-associated virus 8 
serotype has a high tropism for muscle, CNS and the hepatocytes, this, combined with 
the hepatocyte specific thyroid binding globulin (TBG) promoter restricts Cre 
expression specifically to hepatocytes74 (Figure 2.1a, page 32). Viruses were 
administrated by tail vein injection in a 100µl dose at a concentration of 2.5X1011 
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GC/ml. AAV8 viruses were diluted in sterile PBS. Mice were given a 2 week wash 
out period before being placed on toxic injury diets. 
 
Itgb1fl/fl and R26RLSLtdTomato mice 
The β1-Integrinfl/fl (Itgb1fl/fl) mice were purchased from The Jackson Laboratory and 
crossed with the R26RLSLtdTomato mouse (The Jackson Laboratory). The transgene 
Itgb1fl/fl  contains loxP sites flanking exon 3, which, when exposed to Cre recombinase 
results in an excision of exon 3 and a frameshift mutation, preventing translation and 
a loss of the β1-integrin protein254. The ROSA26LSLtdTomato transgene is activated by 
Cre mediated excision of the Stop codon, labelling cells with a fluorescent, heritable, 
genetic marker tdTomato (tdTom). Genotyping was performed using the commercial 
transnetyx genotyping service. All experiments used mice with either homozygous 
alleles for Itgb1fl/fl or Itgb1WT, mice were either heterozygous or homozygous for the 
R26RLSLtdTomato allele. 
 
Tamoxifen induction 
To lineage trace BECs an estrogen receptor bound Cre transgene (CreERT) was inserted 
in to the cytokeratin-19 gene (K19) locus, which expresses CreERT in K19 expressing 
cells, such as the biliary epithelium147. Administration of tamoxifen triggered the 
release of the estrogen bound Cre recombinase, allowing for nuclear translocation and 
genetic recombination, activating R26RLSLTdTomato via excision of the STOP codon 
(Figure 2.1b). Loss of the STOP codon resulted in fluorescent tdTom labelling of the 
biliary epithelial cells at a 40% recombination efficiency284. Recombination in the 
K19creERT LSLtdTomato mice was induced by 3 individual 200µL intraperitoneal (i.p.) 
injections of Tamoxifen (Sigma UK), on alternative days (Monday, Wednesday and 
Friday). The tamoxifen was suspended in sunflower seed oil at a concentration of 
20mg/ml, equating to a 4mg dose per injection. K19Cre animals received 2-3 weeks 
of normal diet after the last Tamoxifen injection, before commencing toxic injury diets.  
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Figure 2.1 – In vivo transgene activation targeting either hepatocytes or BECs  
 
Figure 2.1: Schematic explaining the transgenic models used to lineage trace 
hepatocytes (a) and BECS (b). 
 
K19creERT LSLtdTomato Mice 
The K19CreERT mouse was a gift from Dr Guoqiang Gu (Vanderbilt University)147. It 
was crossed with the R26RLSLtdTomato mouse (The Jackson Laboratory). Mice 
homozygous for the K19CreERT and heterozygous for the R26RLSLtdTomato loci were 
used for lineage tracing experiments.  
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Tissue harvest 
Mice were euthanized according to UK Home Office regulations. Blood was collected 
by cardiac puncture and centrifuged to collect serum. Organs were harvested and either 
directly frozen at -80°C, fixed in 10% formalin (in PBS) for 12 hours, or fixed in 
methacarn for 12 hours. Formalin and methacarn fixed tissue was then stored in 
paraffin. Animals that exceeded the experimental severity protocol boundaries were 
excluded from analysis. Otherwise all animals were included in analysis. 
 
siRNA nanoparticles  
Small interfering RNA (siRNA) formulated in to lipidoid nanoparticles, kindly gifted 
by Victor Koteliansky from Skolkovo Institute for Science and Technology, were used 
to silence Itgb1 mRNA in vivo. These siRNA nanoparticles have been previously 
shown to specifically suppress hepatocyte β1 integrin expression as the lipid 
formulated particle has a high affinity for hepatocytes263,266. 0.5mg/kg doses, in a 
volume of 0.1ml were administrated intravenously via the tail vein to each mouse 
every 5 days according to the schematic on page-107 (Figure 5.1). Depending on the 
experiment, between 2 and 6 doses of siRNA were administrated to each animal. 
Alongside the Itgb1 RNAi nanoparticles, control, anti-luciferase RNAi nanoparticles 
were administrated at the same concentration and frequency.   
 
Histology 
Immuno-histochemistry 
Formalin fixed tissue was embedded in paraffin and cut in to 4µM sections. Heat 
mediated antigen retrieval was performed according to the primary antibody used 
(Table 2.1), heat was generated by a 700Watt microwave. Sections were treated for 
endogenous peroxidase, avidin and biotin. Bloxall (Vector) was first applied to block 
peroxidase activity, this was followed by Avidin and Biotin block (Invitrogen), 
sections were washed between each blocking step. Protein block (Spring Bioscience) 
was applied for 30 minutes before sections were stained overnight at 4°C using 
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primary antibodies listed in Table 2.1. Species specific secondary biotinylated 
antibodies (Vector) targeting the previously applied primary antibody were applied for 
30 minutes. A streptavidin conjugated horseradish peroxidase (HRP), Vectastain 
R.T.U, ABC reageant (Vectar), was then applied for 30 minutes. For the chromogen, 
3,3'-Diaminobenzidine (DAB) (Dako) was added to the sections for approximately 3-
5 minutes. After each antibody and streptavidin application sections were washed with 
PBS. A haematoxylin counter stain was used alongside the DAB to label cell nuclei. 
Isotype controls were used for every immuno-histochemical stain performed (Figure 
2.2). 
 
Immuno-fluorescence 
Formalin fixed tissue, embedded in paraffin was cut into 4µM sections. Again, heat 
mediated antigen retrieval was performed according to the primary antibody used 
(Table 2.1). Sections were blocked with protein block (Spring Bioscience) for 30 
minutes and stained overnight at 4°C using primary antibodies listed in Table 2.1. 
Primary antibodies were detected using fluorescent conjugated secondary antibodies 
(alexa 488/alexa555 and alexa657; invitrogen). Fluorescent secondary antibodies were 
raised in donkey and selected to target the species of the primary antibody. Sections 
were stained with Dapi and mounted with fluromount (SouthernBiotech). 
When two antibodies from the same species were used, SOX9/RFP/HNF4α 
immunofluorescent stain, primary antibodies were applied sequentially. The first 
antibody to be applied, anti-RFP, was detected using a species specific secondary 
antibody (Dako) conjugated to HRP and a Perkin Elmer TSA Plus Cyanine 3, 
signalling amplification, kit (NEL744B001KT). This was followed by a second 
antigen retrieval to denature any antibodies in the tissue and prevent cross-reaction 
with the second primary antibody application.  
 
Histochemistry 
Haematoxylin and Eosin (H&E) stains were automatically produced using a Shandon 
Varistain Automated Slide Stainer. PicroSirius Red (PSR) stains used reagents from 
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Sigma Aldrich; picric acid Cat No:P6744-1GA, fast green Cat No:F7258-25G, direct 
red Cat No: 365548-25G. Staining was performed by the histology department in the 
University of Edinburgh’s Shared University Research Facilities (SURF).  
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Table 2.1 – Primary Antibodies used for immuno-histochemistry and 
immunofluorescence  
Antibody Supplier Fixation 
Antigen 
retrieval 
Antibody 
concentration 
HNF4α (C-19) 
(Goat) 
SC-6556 
Santa Cruz 
Formalin 
Heat mediated, 
Tris EDTA (pH9) 
1/50 
SOX9 (Rabbit) 
ab5535 
Millipore 
Formalin 
Heat mediated, 
Tris EDTA (pH9) 
1/200 
CK19 (TromaIII) 
(rat) 
DSHB Formalin 
Heat mediated, 
sodium citrate 
(pH6) 
1/200 
Smooth Muscle 
Actin α (mouse) 
A2547 Sigma 
Aldrich 
Formalin 
Heat mediated, 
sodium citrate 
(pH6) 
1/2000 
RFP (Rabbit) 
ab62341 
Abcam 
Formalin 
Heat mediated, 
Tris EDTA (pH9) 
1/200 
HNF1β (Rabbit) 
Novus 
Biologicals 
NBP1-89680 
Formalin 
Heat mediated, 
Tris EDTA (pH9) 
1/200 
CYP 2D 
(Sheep) 
Gift from R. 
Wolf, 
University of 
Dundee 
Formalin 
Heat mediated, 
Tris EDTA (pH9) 
1/200 
mCherry (Goat) 
AB0081-500 
SICGEN 
Formalin 
Heat mediated, 
sodium citrate 
(pH6) 
1/200 
Glutamine 
Synthatase 
(Rabbit) 
ab73593 
Abcam 
Formalin 
Heat mediated, 
sodium citrate 
(pH6) 
1/100 
Ki67 (Rabbit) 
ab16667 
Abcam 
Formalin 
Heat mediated, 
sodium citrate 
(pH6) 
1/200 
P21 (Rabbit) 
SC-471 Santa 
Cruz 
Formalin 
Heat mediated, 
sodium citrate 
(pH6) 
1/50 
PCNA (Mouse) ab29 Abcam Formalin 
Heat mediated, 
sodium citrate 
(pH6) 
1/10000 
HMGB1 
(Rabbit) 
ab18256 
Abcam 
Formalin 
Heat mediated, 
sodium citrate 
(pH6) 
1/100 
HNF4α (Rabbit) 
ab181604 
Abcam 
Formalin 
Heat mediated, 
Tris EDTA (pH9) 
1/200 
Β-Catenin 
(Rabbit) 
ab2365 Abcam 
Frozen, 
methanol 
NA 1/200 
Integrin-β1 (Rat) 
MAB1997 
Millipore 
Frozen, 
methanol 
NA 1/200 
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Figure 2.2 – Control images of isotype treated tissue  
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Figure 2.2: Isotype control images. Label above image refers to immuno-stain used in 
conjunction with the isotype control. DNA is stained with either dapi or haematoxylin; 
for fluorescent images, dapi is in grayscale. Generally, secondary antibodies were 
detected with a black and white camera, in these images the fluorescent signal has been 
coloured red. Scale bar: 100µM. 
 
 
Histological analysis 
Microscopy 
For confocal microscopy either a Leica SPE inverted microscope or a Zeiss LSM 780 
was used and images were deconvoluted using Fiji ImageJ. Brightfield images were 
taken using a Nikon Eclipse e600 microscope and Retiga 2000R camera (Q-Imaging) 
and acquired with image pro premier software. The PSR analysis used an AxioScan 
Z.1 (Zeiss) to acquire tiled images at a 20X magnification. De-tiled images were then 
analysed using a standard colour threshold in Fiji Image-J, to measure PSR positive 
fibrosis. Necrotic areas were quantified using H&E histochemistry and the trainable 
WEKA segmentation tool in Fiji Image J, to distinguish between parenchymal and 
necrotic areas. Fluorescent tiled images were generated on a Perkin Elmer Operetta 
high content imaging system, subsequent image stitching was done on Fiji ImageJ 
using the pairwise stitching plugin 285. DAPI, Alexafluore 488, and 555 were detected 
using band paths of 415-480, 495-540 and 561-682nm for 405, 488 543 nm lasers 
respectively.  
 
Fluorescent cell quantification and analysis  
Images were acquired in up to four fluorescent channels at 10X magnification on a 
Perkin Elmer Operetta high content imaging system and subsequently analysed using 
the Columbus software.  An average of 25 images were taken per liver section. One 
field of view corresponds to 1.37mm2.  
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For cell quantification, Dapi stained nuclei were identified based on pixel intensity 
using method ‘B’ with approximately 7000 nuclei identified per field. Nuclear size 
and morphology was then determined (figure 2.3a). Illumination correction and 
background normalization was performed using the sliding parabola module. 
Depending on the experiment, nuclei were then assigned as positive or negative based 
on the mean pixel intensity in the corresponding channel in either the nucleus (HNF4α, 
tdTomato, Ki67, P21 and PCNA) (figure 2.3b) or a 7µM thick region surrounding the 
nucleus (CK19 and αSMA). For each experiment identical thresholds were used in all 
images for assigning nuclei to a specific population. 
To quantify the distribution of tdTomneg (tdTomato) and tdTompos hepatocytes either 
cytokeratin 19 positive (CK19pos) bile ducts or glutamine synthetase positive (GSpos) 
hepatocytes where identified. Non-overlapping zones at various distances form the 
identified cells were established and the number of labelled hepatocytes in each zone 
were quantified (Figure 2.4)   
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Figure 2.3 – Single cell tissue analysis strategy 
 
Figure 2.3: A Perkin Elmer Operetta microscope and the analysis software Colombus 
were used for histological measurements of cell populations. a. Example pipeline used 
to identify cell nuclei in immunofluorescent tissue sections, Method B refers to a pre-
existing algorithm created by Perkin Elmer that identifies nucleus like objects. b. 
Example images from DDC/recovery treated β1-Integrinfl/fl liver and their 
corresponding histograms used to measure nuclei fluorescent intensity and detect 
HNF4α positive and tdTom positive or negative cell populations. Scale bar: 100µM. 
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Figure 2.4 – Strategy to measure distribution of labelled hepatocytes in relation 
to CK19 positive biliary ducts 
 
Figure 2.4: A Perkin Elmer Operetta microscope and the analysis software Colombus 
were used for histological measurements tdTompos hepatocyte distribution in relation 
to CK19pos ducts. a. Example pipeline used to identify CK19pos cell nuclei in 
immunofluorescent tissue sections. b. Example image segmented in to 50µM zones 
from the CK19pos ducts, in each zone nuclei fluorescent intensity is measured to detect 
HNF4αpos hepatocytes which are either tdTom positive (green circles) or negative (red 
circles). Scale bar: 100µM. 
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Quantative PCR analysis 
Liver tissue was homogenised in Trizol (Life Technologies). Homogenates were 
mixed with chloroform (1:5 ratio Chloroform:Trizol) and centrifuged at 4°C, 1’200g, 
for 15 minutes. The aqueous supernatant was removed and mixed 1:1 with 70% 
ethanol. RNA was extracted using a Qiagen RNeasy mini kit and the manufacturer’s 
instructions. Reverse Transcription and Real Time-qPCR was performed using Qiagen 
Quantitect  and Quantifast reagents on a LightCycler 480 II (Roche). Commercial 
primers from Qiagen’s Quantitect range were used; Itgb1 (β1-Integrin (Qiagen, 
QT00155855)); Wnt7b (Qiagen, QT00168812); Wnt9b (Qiagen, QT00144256); 
Wnt11 (Qiagen, QT00103663); Wnt7a (QT00131719); Wnt10 (QT00110089); and 
peptidylprolyl isomerase A (PPIA) (Qiagen QT00247709). Gene expression was 
normalised to the house keeping gene, PPIA. Samples were run in triplicate. The RT2 
Profiler PCR Array, Drug Metabolism: Phase I Enzymes was purchased from Qiagen 
(330231 PAMM- 068Z), and complementary DNA (cDNA) was synthesized from 
extracted RNA using the RT2 First Stand Kit (Qiagen; 330401) according to the 
manufacturer’s instructions. The RT2 Profiler PCR Array was run on a Roche 
LightCycler 480 II with RT2 SYBR Green qPCR Mastermix (Qiagen; 330500), an 
optimal PCR programme was provided by the manufacturer. Analysis were performed 
using the manufacturer’s templates and guidelines.  
 
Protein homogenates and western blots   
Protein was isolated from whole liver. Small, 1-2mm3 pieces of liver were 
homogenised using a tissue tearor (Biospec Products) and lysis buffer (lysis buffer: 
150mM NaCl, 20mM Tris pH7.5, 1mM EGTA, 1mM EDTA, 1% Triton X-100, 2X 
Protease inhibitor Cocktail(Sigma Aldrich)). Samples were mixed at 4°C for 30 
minutes and then centrifuged for 10 minutes at 20’000g. The aqueous supernatant was 
removed and the protein concentration was determined using a Pierce BCA Protein 
Assay Kit (Thermo Scientific). Proteins were separated using SDS-page and 
transferred to nitro cellulose membranes, anti-β1-Integrin (Millipore, MAB1997) 
1/1000 and anti-β-actin (Cambridge Biosciences) 1/2000 were used to detect proteins.  
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Serum analysis 
Serum analysis used commercial kits according to the manufacturer’s instructions; 
alanine transaminase, albumin, bilirubin (Alpha Laboratories); aspartate 
aminotransferase and alkaline phosphatase (Randox laboratories). All kits were 
adapted for use on a Cobas Fara centrifugal analyser (Roche). Serum analysis was 
performed by Dr Forbes Howie in the The Queen’s Medical Research Institute, 
University of Edinburgh 
 
Isolation of biliary ducts and hepatocytes and FACS.  
Hepatocytes and biliary ducts were isolated using the classical perfusion protocol. 
Briefly, animals received an overdose of anaesthetic followed by laparotomy: the 
portal vein was cannulated and injected with Liver Perfusion Medium (Gibco) and 
Liver Digest Medium (Gibco). For duct isolation, ducts were digested and isolated as 
previously described86. For hepatocyte isolation, the liver was removed and 
mechanically disaggregated. The resulting disassociated cells were filtered through a 
70 µ m filter (BD Biosciences). Hepatocytes were purified with a density gradient 
centrifugation286, which isolated cells with hepatocyte morphology and expression of 
CYP2D6 (a mature hepatocyte marker) at a purity greater than 99%87. Briefly, cells 
were layered above various Percoll solutions: 1.06, 1.08, and 1.12 mg ml−1 Percoll 
(Sigma) in PBS. Cells were spun at 750g for 20 min. The hepatocyte layer, between 
the 1.08 and 1.12 mg ml−1 Percoll layers, was collected for Fluorescence Activated 
Cell Sorting (FACS). Purified hepatocytes were sorted on a BD Biosciences Fusion 
Flow Cytometer. Sorted cells where lysed and the RNA was extracted 
 
RNA sequencing analysis 
Whole liver RNA was extracted (see RNA isolation section), RNA integrity was 
analysed and RNA integrity number (RIN) scores determined using a Agilent 2100 
Bioanalyzer and RNA Nano chip. RNA with a RIN >8 was used for RNA sequencing. 
mRNA enrichment (by poly-A capture), library construction and sequencing was 
Chapter 2 – Materials and Methods 
 
44 
 
performed by GATC-Biotech, Germany. Analysis was done on count data by Dr 
Jonathan Manning. Counts were normalised with the Trimmed Mean of M values 
method287 as implemented in the EdgeR method of Bioconductor (version 3.12)288. 
Differential analyses were carried out with edgeR, adjusting for the effect of gender, 
and for ease of interpretation a final matrix was generated using limma’s 
removeBatchEffects method289, with the effect of gender removed. The Gene set 
library was downloaded from version 5.0 of the molecular signatures database290,291. 
Identifiers for the gene set was mapped to mouse via homology relationships 
downloaded from the MGI database (HOM_MouseHumanSequence.rpt, downloaded 
28th August 2015)292. Differences in gene set expression between experimental groups 
were examined via the statistically robust ROAST method293, as implemented in the 
limma package of Bioconductor (version 3.27.4)289. 
For whole genome RNA sequencing (RNA-Seq) of hepatocytes. Samples were treated 
with DNase (Ambion), and sample integrity verified on an Agilent Bioanalyser with 
the RNA Nano chip. Illumina Tru-Seq paired end strand specific sequencing (Illumina, 
USA) was performed on a NextSeq-550 sequencer by the Edinburgh Clinical Research 
Facility, Western General Hospital, Edinburgh, UK. Total RNA (500 ng) underwent 
ribosomal RNA depletion before purification, fragmentation, random hexamer cDNA 
generation, and purification with AMPure XP beads (Beckman-Coulter, USA). 
Multiple indexing adapters were ligated to double-stranded cDNA with subsequent 
hybridization onto flow cells, and DNA fragment enrichment by 15-cycle PCR for 
sequencing. Completed libraries were quantified by qPCR using a KAPA Illumina 
Library Quantification Kit (Illumina, USA) before multiplexing in two equimolar 
pools and running on two flow cells on an Illumina NextSeq 550. Bioinformatics of 
RNA-Seq data was performed by Dr John Thomson. The resulting FastQ files were 
mapped to the reference genome (mm9) using the Tophat alignment tool (version 2) 
on Illumina Basespace software and reads per kilobase per million (RPKM) scores 
calculated for each gene. Differential gene expression was done using DEseq with 
cutoffs of log2(fold change) > 2 and adjusted P < 0.05 within replicates applied. Global 
analysis of total RPKM data sets to assess overall transcriptional states was done by 
calculating and plotting Pearson’s correlation scores visualized as a heatmap with 
Euclidian and Ward clustering applied. Principal component analysis plots were also 
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performed with the use of Illumina Basespace software. Plots for Pearson’s correlation 
scores with hierarchical clustering were also performed on all genes displaying 
significant gene expression changes relative to the control set. Visual examples of the 
transcriptional data were generated by calculating the average expression per group 
(control, β1-integreinfl/fl, AAV8-p21, and biliary duct) and loading onto the Broad 
Institute’s Integrative Genomics Browser 
(https://software.broadinstitute.org/software/igv/download). RPKM values for select 
gene sets (hepatocyte, biliary, Notch signalling, and Wnt signalling) were also 
clustered by Euclidian and Ward methods and expression 
 
Statistical Analysis 
The use of the letter ‘N’ refers to number of biological (mice) replicates used for each 
experimental condition.  
Prism software (GraphPad Software, Inc) was used for all statistical analysis.  Data is 
presented as mean ± s.e.m. n refers to biological replicates. Normal distribution of data 
was determined using D‘Agostino and Pearson omnibus normality test. For parametric 
data, data significance was analysed using a two-tailed unpaired Students t-test. In 
cases where more than two groups were being compared, then a one-way ANOVA 
was used. In cases where two groups were split between two independent variables a 
two-way ANOVA was used. In instances where the N was too small to determine 
normal distribution or the data was non-parametric then a two-tailed Mann Whitney 
U-test was used. F tests were used to compare variances between groups. In cases, 
which randomisation was used (including animal studies), samples were randomized 
by a 'blinded' third party before being assessed separate 'blinded' assessor. Un-blinding 
was performed immediately prior to final data analysis. 
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Loss of hepatocyte β1-Integrin induces liver injury 
and ductular reaction 
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Introduction 
HPCs in the ducts can, hypothetically, differentiate to hepatocytes. However, murine 
lineage tracing studies have produced contradictory results; either reporting a small 
HPC contribution to the hepatocyte epithelium149,150 or none at all56,153,156,159,166. These 
previous investigations used different lineage tracing methods with, established, 
hepatotoxic diet models, CDE and DDC, to stimulate liver injury and provoke HPC 
derived regeneration. Although these models induced DR, it is questionable whether 
the toxic diet models recapitulated the impaired hepatocyte regeneration seen in human 
chronic liver disease33,42 as hepatocyte division and regeneration still occured87,156. In 
an environment where hepatocyte regeneration is compromised, as shown in the 
AhCre MDM2fl/fl model where loss of MDM2 leads to an accumulation of p53 in 
hepatocytes and subsequent senescence, transplanted, biliary derived, HPCs can 
regenerate the hepatocyte epithelium87. To determine if there is an endogenous non-
hepatocyte source of regeneration, when the regenerative ability of the hepatocyte 
epithelium is compromised, I established a model that impairs hepatocyte regeneration 
and simultaneously labels the hepatocyte epithelium.  
Ablation of β1-Integrin in an acute liver injury model reduced hepatocyte growth 
factor signalling and impaired hepatocyte regeneration263. I decided to utilise this 
phenotype with a transgene and viral Cre system that conditionally deletes β1-Integrin 
from hepatocytes to impair their regenerative capabilities. The transgene Itgb1fl/fl  
contains loxP sites flanking exon 3, which, when exposed to Cre recombinase results 
in an excision of exon 3 and a frameshift mutation, preventing translation and a loss 
of the β1-integrin protein254. Throughout this thesis, mice homozygous for the Itgb1fl/fl 
alleles will be referred to as β1-Integrinfl/fl and control mice without the Itgb1fl/fl alleles 
will be designated β1-IntegrinWT. To lineage trace recombined cells a 
ROSA26LSLtdTomato transgene was also included; activation of this transgene via Cre 
mediated excision of the Stop codon labels cells with a fluorescent, heritable, genetic 
marker, tdTomato (tdTom). The Itgb1 KO alleles and the ROSA26LSLtdTomato 
reporter only become activated in the presence of Cre. To Specifically target Cre 
expression to hepatocytes I employed a hepatotropic virus, AAV8.TBG.Cre74,156, to 
ablate  β1-Integrin and concurrently label hepatocytes with tdTom. The adeno-
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associated virus 8 serotype has a high tropism for hepatocytes, this, combined with the 
hepatocyte specific thyroid binding globulin (TBG) promoter restricts Cre expression 
only to hepatocytes74 (Figure 2.1a, page 32). 
This chapter aims to describe the Itgb1fl/fl and ROSA26LSLtdTomato transgenic model 
I used to study liver regeneration.  I will describe the recombination efficiency and 
specificity of the AAV8.TBG.Cre system and the impact of hepatocyte β1-integrin 
deletion on liver homeostasis. 
 
Results  
AAV8.TBG.Cre labelled 99.5% of the hepatocytes in the liver 
To lineage trace hepatocytes the AAV8.TBG.Cre (AAV8Cre) virus was administered 
to both β1-Integrinfl/fl and β1-IntegrinWT mice aged between 6-8 weeks, liver tissue 
was then analysed 14 days later. The hepatotropic virus targeted the 
ROSA26LSLtdTomato locus labelling HNF4αpos hepatocytes tdTom positive (Figure 
3.1a, top left image). In contrast, ROSA26lsltdTomato mice treated with an 
AAV8.TBG.null (AAV8null) virus did not express tdTom in HNF4αpos hepatocytes 
(Figure 3.1a, bottom left image). To quantify the recombination efficiency of the 
AAV8Cre a Perkin Elmer Operetta imaging system was used to measure tdTom 
fluorescent intensity in HNF4αpos hepatocytes, figure 2.3 presents an example of the 
analysis pipeline. Using this method, AAV8Cre was shown to have a recombination 
efficiency of 99.5% in the hepatocyte population (Figure 3.1b). AAV8Cre did not label 
any other cells in the liver, particularly the CK19pos biliary ductal cells (Figure 3.1a). 
To ensure a similar recombination efficiency was occurring in the β1-Integrinfl/fl mice 
the analysis was repeated. No difference in AAV8Cre recombination efficiency was 
detected between β1-IntegrinWT mice and β1-Integrinfl/fl mice (Figure 3.1a and b). 
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Figure 3.1 – AAV8.TBG.Cre labels 99.5% hepatocytes  
 
 
Figure 3.1: a. 14 days post AAV8.TBG.Cre (AAV8Cre) intravenous administration, 
tdTom/HNF4α/CK19 immunofluorescent confocal images, AAV8Cre labels HNF4αpos 
hepatocytes. b. Tissue quantification measuring tdTompos HNF4αpos hepatocytes after 
either AAV8Cre/null administration, 99.5% hepatocytes are tdTom positive in AAV8Cre 
treated livers. N=7 for AAV8Cre mice per condition, N=3 for AAV8null mice. The 
experiment was performed twice. PT = Portal tract. Scale bars: 100µM. 
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AAV8.TBG.Cre ablated β1-Integrin from hepatocytes 
The AAV8Cre recombined loxP sites at the ROSA26lsltdTomato locus 14 days after 
administration. To verify that AAV8Cre was also targeting the loxP sites in the Itgb1 
gene, liver sections were stained with an anti-β1-Integrin antibody and whole liver 
Itgb1 expression was assessed using qPCR. At the protein level hepatocyte β1-Integrin 
could be detected in β1-IntegrinWT livers, demonstrated by membrane positive 
fluorescent staining, which co-localised with the membrane marker β-Catenin (Figure 
3.2a, white arrows). Compared to β1-Integrinfl/fl livers where hepatocyte membrane 
β1-Integrin expression could not be detected, except on small non-parenchymal cells 
(Figure 3.2a, white arrowheads). Western blots of whole liver homogenates for β1-
Integrin supported the immunofluorescence data, with a reduction in β1-Integrin 
protein in the β1-Integrinfl/fl samples (Figure 3.2b and c). Consolidating the protein 
analysis, assessment of whole liver Itgb1 expression with qPCR revealed a significant 
reduction in the β1-Integrinfl/fl liver (Figure 3.2d). 
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Figure 3.2 – AAV8Cre ablated β1-Integrin from β1-Integrinfl/fl hepatocytes  
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Figure 3.2: a. 14 days post AAV8.TBG.Cre (AAV8Cre) intravenous administration, 
β1-Integrin/β-Catenin immunofluorescent confocal images, AAV8Cre ablates β1-
Integrin from β-Cateninpos hepatocyte membranes in β1-Integrinfl/fl mice in contrast to 
β1-IntegrinWT mice (white arrows). b-d. AAV8Cre reduces whole liver β1-Integrin 
protein and gene expression in β1-Integrinfl/fl mice. c. Image densitometry of western 
blot gel, measuring relative ITGB1 in relation to ACTB. d. QPCR measuring relative 
Itgb1 expression in relation of the house keeping gene Ppia. Data are means ± s.e.m.; 
two-tailed unpaired student t-test; * P=0.05. N=3 mice. The experiment was performed 
once. Scale bars: 100µM. 
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Hepatocyte β1-Integrin ablation caused liver injury 
To evaluate the impact AAV8.TBG.Cre/null infection had on liver function serum 
markers associated with liver function (LFTs) were assessed 14 days post viral 
administration. Although there was variation between biological replicates, the mean 
LFT values for each group; AAV8Creβ1-IntegrinWT, AAV8Creβ1-Integrinfl/fl and 
AAV8nullβ1-IntegrinWT were similar to published healthy LFT values (Figure 3.3a-e).  
Ablation of β1-Integrin did not cause abnormal LFTs two weeks after AAV8Cre 
treatment, to test if β1-Integrin ablation effected liver homeostasis over a longer period 
liver tissue and serum was analysed 9 weeks post AAV8Cre injection (Figure 3.4a). 
Serum ALT was raised in the β1-Integrinfl/fl mice; other serum markers of liver 
function were not significantly different but there was greater variation in the LFTs 
from the β1-Integrinfl/fl mice compared to the controls (Figure 3.4b). 
To assess other markers of liver damage, the acknowledged ‘Danger Associated 
Molecular Pattern’ (DAMP) protein HMGB1 was stained for using immuno-
histochemistry. HMGB1 was restricted to the nucleus of hepatocytes in β1-IntegrinWT 
mice, this differed from the β1-Integrinfl/fl mice where a mixture of hepatocytes had 
either nuclear or cytoplasmic HMGB1 expression (Figure 3.4c, white arrowheads and 
arrows). A proportion of the hepatocytes that had cytoplasmic HMGB1 expression no 
longer expressed nuclear HMGB1. 
Long term loss (9weeks) of hepatocyte β1-Integrin caused liver injury, to assess 
hepatocyte regeneration cell markers of proliferation, Ki67, and cell cycle arrest, p21, 
were stained for using immuno-fluorescence. 7.4% of the hepatocytes in the injured, 
β1-Integrin ablated, livers were positive for the proliferation marker Ki67 (Figure 3.5a, 
c). This was 10 times higher when compared to the healthy β1-IntegrinWT samples 
where infrequent Ki67pos hepatocytes were detectable (Figure 3.5a, white arrows). 2% 
of hepatocytes were p21pos in the β1-integrinfl/fl samples, 20 times higher when 
compared to β1-IntegrinWT livers which expressed rare, 0.2%, p21pos hepatocytes.  
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Figure 3.3 – Serum biochemistry 2weeks after viral AAV8Cre/null treatment  
 
Figure 3.3: Serum biochemical markers of liver function 2 weeks post AAV8 
intravenous administration, a. Alanine transaminase (ALT) b. Aspartate transaminase 
(AST) c. Alkaline phosphatase (ALP) d. Albumin and e. Bilirubin. Grey dashed lines 
represent mean values for published, healthy, age matched, C57 bl6 mice294,295. Data 
are means ± s.e.m.;  N=6-8 mice. The experiment was performed twice. 
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Figure 3.4 – β1-Integrinfl/fl mice developed makers of liver injury 9 weeks after 
AAV8Cre administration 
 
Figure 3.4: a. Experimental timeline b. Serum biochemical markers of liver function 
63 days post AAV8Cre intravenous administration, Alanine transaminase (ALT), 
Aspartate transaminase (AST), Alkaline phosphatase (ALP), Albumin and Bilirubin. 
Grey dashed lines represent mean values for published, healthy, age matched, C57 bl6 
mice294,295. c. HMGB1 immuno-histochemistry 9 weeks post AAV8Cre administration, 
β1-Integrinfl/fl samples had hepatocytes where HMGB1 had translocated from the 
nucleus to the cytoplasm (white arrows). Data are means ± s.e.m.; two-tailed unpaired 
t-test; * P=0.05, ** P=0.01. N=9 mice. The experiment was performed twice Scale 
bars: 100µM.  
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Figure 3.5 - β1-Integrinfl/fl livers had abnormal Ki67 and p21 expression 9 
weeks after AAV8Cre treatment  
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Figure 3.5: a,b. 9weeks post AAV8Cre administration, Ki67/HNF4α and p21/HNF4α 
immunofluorescence. c, d.  Single cell quantification measuring Ki67 and p21 in 
HNF4αpos hepatocytes, Ki67 and p21 expression are raised in β1-Integrinfl/fl livers. 
N=3 for p21 measurements and N=8 for Ki67 measurements. Data are means ± s.e.m.; 
Mann-Whitney U test; ** P=0.01. The experiment was performed twice. Scale bars: 
100µM. 
 
 
 
Aberrant bile canaliculi structure in β1-Integrin ablated livers 
Loss of β1-Integrin from hepatocytes caused liver injury stimulating both parenchymal 
proliferation and cell cycle arrest. To determine if there were any further abnormalities, 
specifically to tissue architecture, Haematoxylin and Eosin (H&E) histochemical 
stains were performed.  H&E staining of β1-Integrinfl/fl samples revealed the presence 
of infiltrating cords of cells, disseminated throughout the parenchyma (Figure 3.6a, 
yellow arrowheads).  
To study the bile canaliculi in the β1-Integrinfl/fl livers immunohistochemistry for the 
Multi-Dug Resistance protein (MDR1) was performed. MDR1 staining showed 
changes to the bile canaliculi structure in β1-Integrinfl/fl livers. In normal homeostatic 
conditions, as seen in the β1-IntegrinWT livers, MDR1 is expressed at the apical domain 
of the hepatocyte surface, labelling the canaliculi between adjacent hepatocytes 
(Figure 3.6b; black arrows). Loss of β1-Integrin disrupted the canaliculi structure; 
MDR1 staining revealed aberrant, multi-branched canaliculi (Figure 3.6b; black 
arrowheads). Further immunofluorescent staining of E-Cadherin and MDR1 also 
highlighted changes to the hepatocyte epithelium morphology and structure, caused by 
β1-Integrin loss. 
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Figure 3.6 – β1-Integrin ablated livers had abnormal bile canaliculi 
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Figure 3.6: a. Haematoxylin and Eosin (H&E) histochemistry 9 weeks post AAV8Cre; 
β1-Integrinfl/fl livers had abnormal liver tissue architecture and small infiltrating cells 
were present (yellow arrowheads). b.  Anti-MDR1 immunohistochemistry 9 weeks 
post AAV8Cre; β1-Integrinfl/fl livers had aberrant bile canaliculi (black arrowheads) 
compared to β1-IntegrinWT livers (black arrows). c. E-Cadherin/MDR1 Immuno-
fluorescence; white arrowheads highlight bile canaliculi 9 weeks post AAV8Cre 
administration. Images are representative from stains performed on N=3 mouse 
samples per experimental group. Scale bars: 100µM. 
 
 
 
β1-Integrin ablated livers had prominent ductular reactions  
An anti-CK19 antibody was used to assess the distribution and amount of biliary ductal 
cells in β1-Integrinfl/fl and β1-IntegrinWT livers that had received AAV8Cre and a 9-
week incubation period. β1-Integrinfl/fl livers had a remarkably different biliary ductal 
arrangement compared to the β1-IntegrinWT livers, where the ductal cells had a typical 
morphology, were arranged in to ducts and were located to the portal tract (Figure 3.7a, 
upper panels, arrowheads). In the β1-Integrinfl/fl livers a prominent, invasive, DR could 
be identified (Figure 3.7a, lower panels, arrows and 3.7b), there were significantly 
more, approximately 3-fold increase, CK19pos biliary ductal cells, which had an 
atypical morphology appearing elongated. The CK19pos cells in the β1-Integrinfl/fl liver 
were no longer restricted to the portal tract, disseminating out in to the parenchyma 
(Figure 3.7d).  
Ductular reactions are associated with an activated stromal cell, the myofibroblasts, 
which are α-smooth muscle actin (αSMA) positive. Dual immuno-fluorescence 
revealed the presence of αSMApos myofibroblasts with the invasive CK19pos biliary 
ductal cells (Figure 3.7a). Quantification of αSMApos cells showed a significant, 3-
fold, increase in the β1-Integrinfl/fl liver (Figure 3.7c). 
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Figure 3.7 – Hepatocyte β1-Integrin loss induced ductular reaction 
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Figure 3.7: a. 9 weeks post AAV8Cre administration αSMA/CK19 Immuno-
fluorescence, white arrowheads highlight normal CK19pos biliary cell arrangement in 
the β1-IntegrinWT liver, white arrows highlight atypical CK19pos biliary ductal cells 
undergoing ductular reaction. b. and c. Single cell quantification measuring CK19pos 
and αSMApos cells. PFV=per field of view. d. Single cell quantification measuring 
CK19pos cells distribution in relation to large vessels (white asterisks in panel a.) Data 
are means ± s.e.m.; Man-Whitney U test; *** P=0.0001, N=≥6 biological replicates. 
Experiment was repeated twice. Scale bars: 100µM. 
 
 
 
Hepatocyte β1-Integrin ablation reduced tdTom labelling in hepatocytes, 
leading to periportal patches of tdTomneg hepatocytes 
Long-term hepatocyte β1-Integrin loss disrupted homeostasis and caused liver injury, 
to determine if this phenotype had also altered the cellular source of regeneration I 
assessed hepatocyte tdTom expression in the liver.  
Analysis of tdTomato expression in hepatocytes 2 weeks after AAV8Cre revealed a 
99.5% recombination efficiency (Figure 3.1b). Prolonged loss of hepatocyte β1-
Integrin caused a decrease in the number of labelled hepatocytes, with 84% of 
hepatocytes tdTompos after 9 weeks (Figure 3.8a and b). In contrast, the control, β1-
IntegrinWT livers, maintained a 99.5% tdTom labelling efficiency of the hepatocyte 
epithelium. The degree of tdTomneg hepatocytes in β1-Integrinfl/fl livers varied greatly 
from 1% to 46% of the total hepatocyte population.  
 Further histological inspection of the tdTomato negative (tdTomneg) hepatocytes 
revealed that they were in small patches adjacent to the portal tract (PT) (Figure 3.8a) 
and not the glutamine synthetase (GS) positive hepatocytes that are adjacent to the 
central vein (CV). 
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Figure 3.8 – Long-term β1-Integrin loss caused a reduction in hepatocyte 
labelling 
 
Figure 3.8: a. 9 weeks post AAV8Cre administration tdTom/HNF4α and 
tdTom/Glutamine Synthetase immuno-fluorescence, β1-Integrinfl/fl livers had small, 
periportal, patches of tdTomneg HNF4αpos hepatocytes; PT = portal tract, CV = central 
vein. b. Single cell quantification measuring tdTompos HNF4αpos hepatocytes. Data are 
means ± s.e.m.; Man-Whitney U test; *** P=0.0001. N=≥6 biological replicates. 
Experiment was repeated twice.; Scale bars: 100µM. 
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Discussion 
Loss of hepatocyte β1-Integrin impairs hepatocyte regeneration in acute liver injury263, 
however the long-term effect of β1-Integrin loss in the liver has not been previously 
described. Initial loss of β1-Integrin from the hepatocyte epithelium, 2 weeks post 
AAV8Cre treatment, did not appear to effect liver homeostasis. This is to be expected 
as β1-Integrin is a highly stable protein in vivo, remaining at the cell membrane for 
approximately 10 days266 and therefore any phenotype resulting from β1-Integrin loss  
would not be obvious at day 14. However, at the later time point 9 weeks’ post 
AAV8Cre, β1-Integrin ablation had disrupted liver homeostasis. There were elevated 
makers of hepatocyte damage and gross changes to the tissue architecture noticeable 
by the aberrant bile canaliculi and prominent DRs infiltrating the parenchyma. 
AAV8Cre administration and the subsequent expression of tdTom in β1-IntegrinWT 
hepatocytes did not appear to cause any gross abnormalities to the tissue architecture. 
MDR1 staining of the bile canaliculi was normal and biliary epithelial cells were 
restricted to the portal tract in typical duct formation. Confirming the phenotype 
observed in the β1-Integrinfl/fl liver was exclusively caused by loss of β1-Integrin and 
not by the AAV8 virus or expression of tdTom. 
The nature of the liver injury caused by β1-Integrin ablation was different to 
commonly used mouse hepatotoxic models as it did not produce significantly different 
serum LFT results when compared to the control β1-IntegrinWT mice. A plausible 
reason for this lack of difference would be the timescale of the experiment relative to 
the magnitude of the injury. The half-life of the serum transaminases (ALT and AST) 
is between 17-48 hours296 and therefore any large changes to these serum markers 
would be undetectable over the prolonged injury caused by β1-Integrin loss, similar to 
what is seen in the clinic with human cirrhotic patients296. Serum ALP, albumin and 
bilirubin have a longer half-life ranging from 7-20 days, although some β1-Integrinfl/fl 
mice did have noticeable changes to the levels of these markers, with a trend to 
increase for ALP and bilirubin and decrease for albumin, there was no significant 
differences. To investigate other markers of liver injury I assessed the spatial 
distribution of a recognised liver DAMP, HMGB1297,298. Release of HMGB1 from its 
common, healthy position in the nucleus to the cytoplasm of hepatocytes in the β1-
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Integrinfl/fl mouse suggests that it is acting as a DAMP for injured β1-Integrin deficient 
hepatocytes.  
The pathophysiology caused by β1-Integrin loss could involve multiple mechanisms, 
the disruption of growth factor signalling has been previously mentioned263. 
Additional features recognised in this chapter such as the loss in hepatocyte epithelial 
integrity and activation of inflammatory pathways through DAMPs could also be 
contributing to liver injury. The integrin adhesome has multiple cellular functions244 
and it is therefore difficult to ascertain how perturbations to the integrin adhesome by 
deletion of β1-Integrin specifically damages hepatocytes.  
AAV8.TBG.Cre mediated β1-Integrin ablation did not completely remove β1-Integrin 
expression from the liver as it is widely expressed on non-parenchymal cells such as 
stellate cells/myofibroblasts, endothelial cells and Kupffer cells263. However; AAV8Cre 
did specifically ablate β1-Integrin expression from hepatocytes. This specificity was 
advantageous as loss of β1-Integrin from other cell types would have added complexity 
to an already complex phenotype and may have confounded the results. 
The labelling efficiency of the AAV8Cre-tdTom system was strikingly robust; 99.5% 
of the hepatocyte epithelium was tdTom positive, rare non-recombined hepatocytes 
were occasionally detected. This recombination efficiency makes the AAV8Cre-tdTom 
system a powerful tool to detect non-hepatocyte derived regeneration as any non-
hepatocyte source of regeneration would dilute the 99.5% epithelial labelling. In the 
healthy β1-IntegrinWT liver the hepatocyte epithelium retained a 99.5% labelling 
efficiency 9 weeks after AAV8Cre treatment, confirming that under homeostatic 
conditions hepatocytes are the sole source of regeneration127,156,157. In contrast, the 
defective β1-Integrinfl/fl liver showed a marked decrease in the number of labelled 
hepatocytes. Patches of tdTomneg hepatocytes were found in the hepatocyte epithelium 
of all β1-Integrinfl/fl mice. These patches appeared periportally which suggested they 
were not randomly distributed through the parenchyma. There was also great variation 
in the degree of tdTomato labelled hepatocytes between livers from the β1-Integrinfl/fl 
mice. This variation could be caused by the extended duration (9weeks) of the 
experiment, allowing for large differences between samples to form. A better 
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understanding of the β1-Integrinfl/fl disease mechanism may also explain the large 
variation.  
Additionally, the β1-Integrinfl/fl liver had prominent ductular reactions, recognisable 
by the invasive, atypical CK19pos cells and neighbouring activated αSMApos 
myofibroblasts. The ductular reaction also had a peri-portal origin, coinciding with the 
appearance of the tdTomneg hepatocytes. This observation supports a hypothesis that a 
biliary derived HPC in the ductular reaction can regenerate the hepatocyte epithelium 
by differentiating in to tdTomneg hepatocytes.  
These data together demonstrate that AAV8.TBG.Cre mediated β1 Integrin ablation 
causes parenchymal damage, triggering both hepatocyte regeneration and a ductular 
reaction with 16% of parenchymal regeneration emanating from a non-parenchymal 
origin. To investigate whether this non-parenchymal contribution is enhanced during 
toxic liver injury I will injure both β1-IntegrinWT and β1-Integrinfl/fl livers and evaluate 
the emergence of tdTomneg hepatocytes. 
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Chapter 4 
 
Liver injury diets combined with hepatocyte β1-
Integrin deletion results in a delayed regenerative 
response from cells of non-hepatocyte origin 
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Introduction 
The deletion of hepatocyte β1-Integrin disrupted liver homeostasis and resulted in the 
appearance of small un-labelled periportal hepatocyte patches, implying hepatocyte 
regeneration can derive from a non-hepatocyte origin. To further stimulate non-
hepatocyte derived regeneration, I decided to induce liver injury and regeneration 
using injury diets that contain hepatotoxic agents. I damaged β1-integrinWT and β1-
integrinfl/fl livers with three independent regimes: DDC (3,5-diethoxycarbonyl-1,4-
dihydrocollidine) diet, methionine and choline deficient (MCD) diet, and 
thioacetamide (TAA) in the drinking water. DDC imitates human cholestatic liver 
disease, causing ductular reaction and portal fibrosis280,299, in severe incidents bile 
infarcts arise causing parenchymal necrosis. MCD, a model of NASH, has a high 
fructose and fat content, the absence of methionine and choline disrupts mitochondrial 
β-oxidation and the synthesis of low density lipoprotein resulting in steatosis, 
inflammation, necrosis and liver fibrosis281. TAA is a model of liver fibrosis, which, 
when applied chronically can generate liver cancer. The pathophysiology of TAA 
arises when TAA is metabolised in the zone 1 and zone 3 hepatocytes, generating 
reactive oxygen species that disrupt the cell’s macro-molecules, resulting in necrosis 
and eventually fibrosis281.  
Utilising these distinct liver injury models, I designed an experiment that involved the 
initial ablation of hepatocyte β1-Integrin followed by exposure to injury diet and 
subsequent tissue analysis at various time points in recovery (Figure 4.1). A two week 
wash out period after AAV8Cre administration was used to ensure no residual AAV8Cre 
would interfere with hepatocyte labelling during injury and regeneration156. Using this 
experimental approach, I could study the regenerative dynamics in livers with a 
functioning hepatocyte epithelium (β1-IntegrinWT) and a defective one (β1-
Integrinfl/fl). 
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Figure 4.1 – Experimental time line to study the regenerative dynamics in β1-
IntegrinWT and β1-Integrinfl/fl livers after administration of a liver injury diet  
 
 
 
Results 
Hepatocyte β1-integrin loss delayed recovery after DDC induced liver injury  
To stimulate liver injury and regeneration mice were maintained on a hepatotoxic diet, 
DDC, for a 7-10-day period. During initial experiments a small proportion of mice 
from both experimental groups, β1-IntegrinWT and β1-Integrinfl/fl, exceeded the 
permitted maximum weight loss limit. These animals were taken off DDC diet before 
the planned 10-day schedule, therefore a 7-day injury regime became the standard. To 
assess liver function and the degree of injury caused by DDC, LFTs of blood serum 
were performed at peak injury and subsequent time points after DDC diet was 
removed.   
LFT measurements in both the β1-IntegrinWT and β1-Integrinfl/fl mice were elevated at 
peak injury indicating that DDC diet had reduced liver function and caused liver injury 
(Figure 4.2a-d). Mice from the β1-IntegrinWT group had higher serum ALT, AST and 
bilirubin at peak injury compared to the β1-Integrinfl/fl group. However, the high 
amounts of serum ALT, AST, ALP and bilirubin in the β1-IntegrinWT group rapidly 
decreased during recovery; serum bilirubin returned to normal after 2-days of recovery 
followed by ALT, AST, ALP at day-7 of recovery.  In stark contrast, the β1-Integrinfl/fl 
group retained elevated serum ALT, AST, ALP and bilirubin, which did not return to 
normal until day-14 of recovery, with serum ALP and bilirubin increasing further 
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during the first 3-days of recovery. The LFTs affirmed that DDC diet induces liver 
injury and indicated that hepatocyte β1-Integrin ablation was delaying the regenerative 
response.   
Changes to body weight can be associated with liver damage, mice were weighed daily 
to monitor the impact of DDC diet during the experiment. All animals from both the 
β1-IntegrinWT and β1-Integrinfl/fl groups had a transient decrease in body weight when 
given DDC diet (Figure 4.2e). The β1-IntegrinWT group returned to pre-injury body 
weight 2-days after re-introduction to normal diet. Similar to the trend seen with the 
serum LFTs, the duration of the β1-Integrinfl/fl groups return to pre-injury body weight 
was delayed, re-gaining their pre-injury weight 12-days after removal from DDC diet.  
To further assess DDC induced liver damage, HMGB1 expression was investigated 
using immuno-histochemistry. Early in the recovery phase, day-3, cytoplasmic and 
corresponding nuclear loss of HMGB1 could be detected in a subset of hepatocytes 
from the β1-IntegrinWT and β1-Integrinfl/fl groups, indicating the release of HMGB1 
due to injury. Cytoplasmic HMGB1 positive hepatocytes were common around areas 
of necrosis and more frequent in β1-Integrinfl/fl livers (Figure 4.2f, white arrows). 
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Figure 4.2 – Hepatocyte β1-integrin ablation resulted in a delayed recovery 
after DDC induced liver injury 
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Figure 4.2 – continued 
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Figure 4.2: a – d. Serum markers associated with liver function from either β1-
IntegrinWT or β1-Integrinfl/fl mice before, during and after DDC diet induced liver 
injury; grey dashed lines represent mean values for published, healthy, age matched, 
C57 bl6 mice294,295. e. Mouse body weight measurements during DDC diet and the 
subsequent recovery. f. Immuno-histochemistry for the DAMP HMGB1; High power 
images correspond to numbered inserts (1-3). Data are means ± s.e.m. N=5 biological 
replicates; Scale bars: 100µM. 
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Ki67 and p21 expression was altered after DDC injury in livers with hepatocyte 
β1-integrin ablation  
DDC diet induced liver injury in both the β1-IntegrinWT and β1-Integrinfl/fl groups, 
triggering a delayed recovery phenotype in β1-Integrinfl/fl livers. To determine if the 
delay was caused by either alterations to proliferation or cell cycle arrest hepatocyte 
Ki67 and p21 expression were examined.  
During the early phase of recovery, between day1-3, both β1-IntegrinWT and β1-
Integrinfl/fl hepatocytes upregulated Ki67 expression, with a higher proportion of 
hepatocytes expressing Ki67 in the β1-IntegrinWT group (Figure4.3a). Ki67 expression 
in β1-IntegrinWT hepatocytes declined after day-3 of recovery, returning to a constant 
4% of all hepatocytes expressing Ki67 by day 7 of recovery (Figure4.3c).  In the β1-
Integrinfl/fl group 10-12% of all hepatocytes continued to express elevated levels of 
Ki67, returning to β1-IntegrinWT level at Day-14 of recovery.  
The β1-IntegrinWT and β1-Integrinfl/fl groups had a similar hepatocyte p21 expression 
profile during the first three days of recovery (Figure4.3b and c). 10-20% of 
hepatocytes were p21 positive at the end of DDC treatment, increasing to over 20% at 
day-1 of recovery followed by a decline at day-2 and 3. After day-3 of recovery the 
expression profiles of the β1-IntegrinWT and β1-Integrinfl/fl groups diverged, β1-
IntegrinWT livers had near undetectable amounts of hepatocyte p21 expression. In 
contrast, the β1-Integrinfl/fl livers maintained elevated hepatocyte p21 expression, with 
10% of hepatocytes p21pos at day 7 of recovery and returning to β1-IntegrinWT levels 
at Day-14 of recovery. Generally, Ki67 and p21 expression was mutually exclusive 
with rare dual positives occasionally detectable (Figure 4.3d). 
The differences in Ki67 and p21 expression between the β1-IntegrinWT and β1-
Integrinfl/fl groups in recovery followed a developing theme: in the β1-IntegrinWT 
group p21/Ki67 expression declined after Day-3 of recovery, expression was 
prolonged in the β1-Integrinfl/fl group not declining until after day-7 of recovery. In 
both groups the decline of p21 and Ki67 expression coincided with the loss of injury 
markers (Figure 4.2). 
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Figure 4.3 – DDC diet induced prolonged expression of Ki67 and p21 in 
hepatocytes after liver injury 
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Figure 4.3: a and b. Quantification of Ki67 and p21 expression in hepatocytes during 
DDC induce liver injury and subsequent recovery. c. Panel of representative images 
displaying HNF4α/p21 and HNF4α/Ki67 immuno-fluorescence from livers at day 7 
of recovery, after DDC induced liver injury. d. Ki67/p21 immuno-fluorescent image 
of β1-Integrinfl/fl liver at day 7 of recovery post DDC induced liver injury. White 
arrowheads highlight dual positive cells. Data are means ± s.e.m.; 2-way ANOVA with 
Bonferroni post-test; * P=0.05; N=5 biological replicates. Scale bars: 100µM. 
 
 
 
Hepatocyte β1-integrin ablation and DDC injury resulted in a highly necrotic 
event early in recovery  
A hepatocyte proliferation defect did not appear to be causing the β1-Integrinfl/fl 
associated delay in liver recovery. To ascertain if there was a greater turnover of tissue 
in the recovering β1-Integrinfl/fl liver a tissue necrosis analysis was performed.  
Histological analysis of β1-IntegrinWT and β1-Integrinfl/fl livers revealed a higher 
propensity for necrosis in the β1-Integrinfl/fl group. 12.5% of the parenchyma was 
necrotic in the β1-Integrinfl/fl livers at peak injury compared to 1.3% in the β1-
IntegrinWT liver. Between day 1-3 of recovery the β1-IntegrinWT liver displayed a 
transient 3.5-fold increase, 5% of the parenchyma, in necrosis. In contrast, there was a 
2-fold decline in necrosis during the first day of recovery in β1-Integrinfl/fl livers, down 
to 4.4% parenchymal necrotic area, followed by a major necrotic event between day-
2 and 3 resulting in 23.5% of the parenchyma becoming necrotic (Figure 4.4a, black 
asterisks, and b).  
The H&E histochemistry used to study liver necrosis also revealed another significant 
phenotype in the β1-Integrinfl/fl liver. Cords of small cells were observed infiltrating 
the parenchyma at day-7 and 14 of recovery (Figure 4.4a, black arrows).  
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Figure 4.4 – β1-Integrinfl/fl livers were highly necrotic early in recovery after 
DDC induced liver injury       
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Figure 4.4 – continued  
 
 
Figure 4.4: a. H&E histochemistry from β1-IntegrinWT and β1-Integrinfl/fl livers during 
DDC diet and subsequent recovery; black asterisks = necrotic areas, black arrows = 
small infiltrating cells. b. Necrosis analysis using pixel based image segmentation to 
measure necrotic areas in H&E sections from β1-IntegrinWT and β1-Integrinfl/fl livers. 
Data are means ± s.e.m.; 2-way ANOVA with Bonferroni post-test; * P=0.05, *** 
P=0.005; N=5 biological replicates. Scale bars: 100µM. 
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DDC induced ductular reaction  
To further investigate the infiltrating cells detected at day-7 and 14 of recovery in the 
β1-Integrinfl/fl liver (Figure 4.4a), samples were stained for the biliary epithelial marker 
CK19. Atypical CK19pos biliary epithelial ductal cells were identified in β1-Integrinfl/fl 
livers from day 3 of recovery. The atypical ductal cells appeared elongated and 
invasive (Figure 4.5a white arrowheads) when compared to CK19pos ductal cells in the 
β1-IntegrinWT livers, which were arranged into biliary ducts with lumens (Figure 4.5a 
white arrows). From day 7 of recovery the atypical biliary epithelial cells in the β1-
Integrinfl/fl liver were no longer restricted to the portal tract, disseminating in to the 
parenchyma (Figure 4.5a and 4.7a). Both the β1-Integrinfl/fl and β1-IntegrinWT liver had 
an approximate 3-fold increase in CK19pos cells during DDC diet induced liver injury, 
proceeded by a transient decline in CK19pos cells at day 1 and 2 of recovery (Figure 
4.5b). The β1-IntegrinWT liver had a subsequent CK19pos cell expansion phase between 
day 3 and 7 of recovery where the number of CK19pos cells increased 4-fold, at day 14 
of recovery the number of CK19pos cells had decreased back to pre-injury levels.  At 
day 7 of recovery in the β1-Integrinfl/fl group, quantification of the CK19pos cell 
population revealed a significant, 8-fold, increase in CK19pos cells (Figure 4.5b). Large 
amounts of CK19pos cells, remained in the liver during the recovery phase, with 
elevated CK19pos cell numbers still detectable 42days after removal of DDC diet.  
To determine if the β1-Integrinfl/fl DDC diet induced ductular reactions were associated 
with activated myofibroblasts, sections were stained for the activated myofibroblast 
marker, αSMA. Large amounts of activated myofibroblasts surrounded the atypical 
CK19pos ductal cells in the β1-Integrinfl/fl group (Figure 4.5a).  There was a 3-fold 
increase in αSMApos cells preceding the increase in CK19pos cells, beginning at day-3 
of recovery and decreasing after day-7. Quantification of αSMApos cells in the control, 
β1-IntegrinWT group, revealed a similar profile to the CK19pos cell quantification with 
an increase at peak injury and day 3-7 of recovery, approximately 300-400 αSMApos 
cells PFV, followed by a return to normal, pre-injury, amounts at day 14 of recovery.  
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Figure 4.5 – Hepatocyte β1-Integrin deletion combined with DDC induced liver 
injury enhanced ductular reaction during recovery 
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Figure 4.5: a. Confocal images of ductular reaction, αSMA/CK19 immuno-
fluorescence on β1-IntegrinWT and β1-Integrinfl/fl livers at various time points after 
DDC induced liver injury; white arrows = typical biliary ductal cells, white arrowheads 
= atypical biliary ductal cells. b and c. Single cell quantification measuring CK19pos 
cells and αSMApos cells in β1-IntegrinWT and β1-Integrinfl/fl livers before, during and 
after DDC induce liver injury. PFV=per field of view. Data are means ± s.e.m.; 2-way 
ANOVA with Bonferroni post-test; * P=0.05, ** P=0.01, *** P=0.005; N=5 biological 
replicates. Scale bars: 100µM. 
 
 
 
β1-integrin ablation and DDC injury resulted in liver fibrosis  
Ductular reactions are associated with liver fibrosis, to determine if the β1-Integrinfl/fl 
DDC diet induced ductular reaction had accompanying fibrosis, livers were stained for 
collagen with PicroSirius Red (PSR). DDC induced periportal liver fibrosis in both the 
β1-IntegrinWT and β1-Integrinfl/fl groups (Figure4.6a and b). In the β1-Integrinfl/fl group 
fibrosis continued to increase, but was no longer confined to the portal tract, forming 
bridging, fibrous septa.   
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Figure 4.6 – β1-Integrinfl/fl livers developed substantial fibrosis after DDC 
induced liver injury 
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Figure 4.6 – continued  
 
 
 
Figure 4.6: a. PicroSirius Red (PSR) histochemistry from β1-IntegrinWT and β1-
Integrinfl/fl livers during DDC diet and subsequent recovery. b. Fibrosis analysis, 
percentage of pixels PSR positive, before, during and after DDC injury. Data are 
means ± s.e.m.; 2-way ANOVA with Bonferroni post-test; * P=0.05, *** P=0.005; 
N=5 biological replicates. Scale bars: 100µM. 
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DDC injury and subsequent regeneration reduced hepatocyte labelling in the 
β1-Integrinfl/fl liver 
There was greater cell death and a prolonged regenerative period in the β1-Integrinfl/fl 
group; to determine if the hepatocyte epithelium was the only source of cell 
regeneration tdTomato labelling in the liver was investigated. In β1-Integrin deficient 
livers large areas of the parenchyma were tdTomneg (Figure 4.7a, insert 2) at day-14 of 
recovery. CK19pos ductal cells were predominantly distributed between the remaining 
tdTompos cells (Figure 4.71, insert 1 white arrows). In contrast, livers from the β1-
IntegrinWT group had no tdTomneg patches, the parenchyma was completely tdTompos 
and CK19pos ductal cells were in the bile ducts at the portal tract (Figure 4.7a, insert 3 
and 4, white arrowheads).  
The tdTomneg cells identified in the β1-Integrinfl/fl liver expressed the mature 
hepatocyte markers CYP2D and HNF4α (Figure 4.8b and 4.9a). Interestingly, at peak 
injury tdTompos cells lost their CYP2D expression (Figure 4.8a), however these cells 
were not observed at day-14 of recovery. The tdTomneg hepatocytes appeared between 
day-3-7 of recovery and eventually reconstituted 25% of the hepatocyte epithelium in 
the β1-Integrinfl/fl group (Figure 4.9b).  
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Figure 4.7 – 14 days after DDC induced liver injury parenchymal tdTomneg 
areas were detected in β1-Integrinfl/fl livers  
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Figure 4.7: a. Tiled image, tdTom/CK19 immuno-fluorescence on β1-IntegrinWT and 
β1-Integrinfl/fl livers 14 days after DDC induced liver injury; white arrows = infiltrating 
CK19pos biliary ductal cells, white arrowheads = CK19pos biliary ductal cells at the 
portal tract. Scale bars: 100µM. 
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Figure 4.8 – Parenchymal tdTomneg areas were positive for the mature 
hepatocyte maker CYP2D 
 
 
Figure 4.8: Confocal images. a. CYP2D/tdTom immuno-fluorescence of β1-
IntegrinWT and β1-Integrinfl/fl livers after 7 days of DDC diet, a subset of periportal 
tdTompos cells were CYP2Dneg. b. CYP2D/tdTom immuno-fluorescence of β1-
IntegrinWT and β1-Integrinfl/fl livers 14 days after DDC induced liver injury. Scale bars: 
100µM. 
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Figure 4.9 – Hepatocyte tdTom labelling was reduced by 25% after DDC 
induced liver injury in β1-Integrinfl/fl livers  
 
 
Figure 4.9: a. Confocal images of tdTom labelling, tdTom/HNF4α immuno-
fluorescence on β1-IntegrinWT and β1-Integrinfl/fl livers 14 days after DDC induced 
liver injury. b. Single cell quantification measuring tdTom positive and negative 
HNF4αpos hepatocytes in β1-IntegrinWT and β1-Integrinfl/fl livers before, during and 
after DDC induce liver injury. Data are means ± s.e.m.; 2-way ANOVA with 
Bonferroni post-test; *** P=0.005; N=5 biological replicates. Scale bars: 100µM. 
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DR and loss of labelled hepatocytes also occurred with other liver injury 
models 
To verify the altered hepatocyte regeneration phenotype observed in the DDC injured 
β1-Integrinfl/fl livers was not an artefact of the DDC model the experiment was repeated 
using the TAA and MCD liver injury models (Figure 4.1).  The MCD and TAA liver 
injury models recapitulated the phenotype seen in the β1-Integrinfl/fl group. There was 
a reduction in the proportion of tdTompos HNF4αpos hepatocytes from 99.5% to 75-
80% 14 days after removal of the hepatotoxic agent (Figure 4.10a and c). A small 
percentage of hepatocytes, 6.5%, were tdTomneg after 21 days of the TAA model 
(Figure 4.10a). 
Another common feature observed in β1-Integrinfl/fl livers treated with TAA and MCD 
were elevated amounts of CK19pos biliary ductal cells at day-14 of recovery. Although, 
the MCD and DDC treated livers had approximately 3 times more CK19pos cells PFV 
than the TAA treated group (Figure 4.10b).  
The hepatocyte epithelium in the control, β1-IntegrinWT, livers subjected to the MCD 
injury model continued to remain tdTompos. A small decrease in labelled hepatocytes, 
4%, was detected in the, β1-IntegrinWT TAA treated livers at day-14 of recovery. MCD 
and TAA induced liver injury did not stimulate an increase in the number of CK19pos 
biliary ductal cells in the β1-IntegrinWT group (Figure 4.10a-c). 
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Figure 4.10 – β1-Integrinfl/fl livers had reduced hepatocyte labelling and 
ductular reactions when injured with alternative liver injury models 
 
 
Figure 4.10: a, b. Quantification measuring tdTom positive and negative HNF4αpos 
hepatocytes and CK19pos cells in β1-IntegrinWT and β1-Integrinfl/fl livers before, during 
and after either TAA or MCD induced liver injury. c. Confocal images of tdTom 
labelling, tdTom/HNF4α immuno-fluorescence on β1-IntegrinWT and β1-Integrinfl/fl 
livers 14 days after MCD induced liver injury. Data are means ± s.e.m.; 2-way 
ANOVA with Bonferroni post-test; *** P=0.005; N=3 for MCD and N=2 TAA, 
biological replicates. Scale bars: 100µM. 
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tdTomato negative hepatocytes were adjacent to the DR  
The loss of β1-Integrin from hepatocytes altered the regenerative response, with 
tdTomneg hepatocytes appearing in the parenchyma between day-3-7 of recovery. To 
investigate the spatial location of the emerging tdTomneg hepatocytes I analysed 
histology of β1-Integrinfl/fl livers from day 7 of recovery.  
tdTomneg hepatocytes were adjacent to the CK19pos/SOX9pos ductular reaction (Figure 
4.11a). The distribution of tdTomneg hepatocytes could be quantified using the 
PerkinElmer ‘Columbus’ software to segment regions of tissue at various distances 
from the CK19pos ductular reaction (Figure 2.4, page 39).  The location of tdTomneg 
hepatocytes was inversely correlated to the distance from CK19pos cells (Figure 
4.11b,c). Another feature identified at day 7 of recovery was the presence of 
tdTomneg/SOX9pos/HNF4αpos cells at the border between the new hepatocytes and the 
ductular reaction (Figure 4.11a, yellow arrows). This rare cell type may represent a 
putative intermediate cell state between SOX9pos biliary cells and HNF4αpos 
hepatocytes.   
Hepatocyte ductal-metaplasia was also detectable at day-7 of recovery, previously 
labelled, tdTompos hepatocytes had downregulated HNF4α and were expressing SOX9 
(Figure 4.11a, cyan arrowheads). Along with the change in cell markers the tdTompos 
cells had an altered morphology, appearing small and duct like. 
 
 
 
 
 
 
 
 
 
Chapter 4 – Results 
 
91 
 
Figure 4.11 – At day 7 of recovery tdTomneg hepatocytes emerged adjacent to 
the ductular reaction 
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Figure 4.11: a. Confocal images of tdTom/HNF4α/CK19 and tdTom/HNF4α/SOX9 
immuno-fluorescence on β1-Integrinfl/fl livers 7 days after DDC induced liver injury; 
white arrows = biliary ductal cells, either CK19pos or SOX9pos; yellow arrows = 
putative, intermediatory, cells expressing the hepatocyte marker HNF4α and the 
biliary epithelial marker SOX9; Cyan arrowheads = hepatocyte-ductal metaplasia, 
tdTompos/SOX9pos/HNF4αneg cells. b and c. Quantification of distribution of tdTomneg 
hepatocytes in relation to CK19pos biliary ductal cells; b. Data are mean ± s.e.m. c. 
Presents paired data for each β1-Integrinfl/fl liver analysed. N=5 biological replicates 
Scale bars: 100µM. 
 
 
 
At Day 14 of recovery tdTomato positive hepatocytes were mainly distributed 
around the central vein  
There was a bias to the distribution of emerging tdTomneg hepatocytes at day-7 of 
recovery with the tdTomneg hepatocytes adjacent to the ductular reaction, which 
originates from the portal tract. To investigate if there was a bias in the distribution of 
remaining tdTompos hepatocytes towards a central venous location, distal to the portal 
tract, tdTom positive hepatocytes were quantified in relation to their position with the 
central venous (CV), glutamine synthetase (GS) positive, hepatocytes (Figure 4.12a).  
At day-14 of recovery, post DDC induced liver injury, remaining tdTompos hepatocytes 
were arranged around GSpos CV, decreasing in density as the distance from the GSpos 
CV increased (Figure 4.12b,c). 
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Figure 4.12 – At day 14 of recovery remaining tdTompos hepatocytes were 
concentrated in zone 3 around the central veins 
 
 
Figure 4.12: a. tdTom/GS/CK19 immuno-fluorescence on β1-Integrinfl/fl livers 14 
days after DDC induced liver injury. b and c. Quantification of tdTompos hepatocytes 
distribution in relation to GSpos central veins; b. Data are mean ± s.e.m.. c.  Presents 
paired data for each β1-Integrinfl/fl liver analysed. N=6 biological replicates Scale bars: 
100µM. 
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tdTomato negative hepatocytes were more proliferative and had smaller nuclei 
when compared to neighbouring tdTomato positive hepatocytes  
To further characterise biological differences between the tdTompos and tdTomneg 
hepatocytes I compared cell proliferation, nuclear size and β1-Integrin expression 
between the two groups.  
Loss of β1-Integrin disrupts growth factor signalling, and impairs hepatocyte 
proliferation263. To detect this phenotypic difference ‘Proliferating Cell Nuclear 
Antigen’ (PCNA) expression was examined between the tdTomneg hepatocytes and 
their neighbouring tdTompos hepatocytes. Histological analysis revealed that tdTomneg 
hepatocytes were more proliferative than neighbouring tdTompos hepatocytes, and the 
average nuclear size was smaller in the tdTomneg hepatocyte population (Figure 
4.13a,b). At the later recovery time point, 42 days after DDC induced liver injury, 
tdTomneg hepatocytes were no longer highly proliferative when compared to the 
tdTompos hepatocytes, but continued to display a smaller nuclear size.   
AAV8Cre induced gene recombination labelled 99.5% of hepatocytes tdTompos and 
ablated β1-Integrin; to verify that the new tdTomneg hepatocytes were either β1-
Integrin positive or negative anti β1-Integrin immunohistochemistry was performed 
on tissue from day 14 of recovery. Analysis of serial tissue sections confirmed that 
tdTomneg hepatocytes were positive for β1-Integrin (white dashed line and white 
arrowheads, Figure 4.13d) and remaining tdTompos hepatocytes were β1-Integrin 
negative.  
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Figure 4.13 – Proliferation was more frequent and nuclear size was smaller in 
the β1-Integinpos tdTomneg hepatocytes  
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Figure 4.13 – continued 
 
 
 
Figure 4.13: a. Representative PCNA/HNF4α/tdTom immunofluorescent image 
comparing PCNA expression and nuclear size between tdTompos and tdTomneg 
hepatocytes in β1-Integrinfl/fl livers 14 days after DDC induced liver injury. b and c. 
Liver tissue analysis of β1-Integrinfl/fl mice at day 14 and 42 recovery post DDC injury; 
quantifying PCNA expression and nucleus size in both tdTompos and tdTomneg 
hepatocytes (HNF4αpos). Paired T-test, ** P=<0.01, *** P=0.005; N=7 biological 
replicates. d. Serial sections of β1-Integrinfl/fl liver 14 days after DDC induced liver 
injury, tdTomneg hepatocytes are β1-Integrin positive (white arrowheads). Scale bars: 
100µM. 
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Whole liver RNA sequencing at day 7 of recovery  
To identify potential factors and signalling pathways that may have a role in regulating 
non-hepatocyte derived regeneration I performed whole liver RNA-Seq on DDC 
treated β1-Integrinfl/fl and β1-IntegrinWT livers at day-7 of recovery, when new 
tdTomneg hepatocytes began to appear.   Whole liver RNA from β1-Integrinfl/fl and β1-
IntegrinWT livers at DDC peak injury was extracted and sequenced to determine if the 
β1-Integrinfl/fl and β1-IntegrinWT livers responded differently to DDC induced liver 
injury. Subsequent bioinformatics were performed by Dr Jonathan Manning of the 
Centre for Regenerative Medicine’s bioinformatic services. 
Principle component analysis of the RNA-Seq data from all 4 groups showed samples 
from each group clustered together. The global gene expression between β1-Integrinfl/fl 
and β1-IntegrinWT livers at peak injury did not vary largely in comparison to day-7 of 
recovery (Figure 4.14a). Gene set analysis using the MSigDB Hallmark Gene set and 
a false discovery rate (FDR) threshold of 0.05 identified 34 gene sets differentially 
expressed between the β1-Integrinfl/fl and β1-IntegrinWT livers at day-7 of recovery 
(Figure 4.14b). 15 of these gene sets could be broadly categorised under inflammation 
and injury response (Table 4.1), all of which were increased in the β1-Integrinfl/fl liver. 
5 Gene sets associated with liver function had a decreased expression in the β1-
Integrinfl/fl liver compared the β1-IntegrinWT (Table 4.2). 10 signalling gene sets were 
also upregulated in the β1-Integrinfl/fl liver (Table 4.3), within this group of signalling 
gene sets were the Notch signalling pathway and the Wnt/β-Catenin signalling 
pathway.  
In the β1-Integrinfl/fl liver there was increased expression of genes in the ‘myogenesis’ 
and ‘epithelial mesenchymal transition’ gene sets, which correlates strongly with the 
prominent DR observed at the day-7 of recovery time point (Figure 4.5).  
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Figure 4.14 – Whole liver RNA-Seq reveals gross differences between 
regenerating β1-IntegrinWT and β1-Integrinfl/fl livers 
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Figure 4.14: Whole liver RNA-Seq after DDC diet induced liver injury and 
regeneration. a. 3D Principle component analysis between 4 groups; β1-IntegrinWT 
peak injury (7days of DDC), β1-Integrinfl/fl peak injury, β1-IntegrinWT day 7 of 
recovery and β1-Integrinfl/fl day 7 of recovery. b. MSigDB Hallmark Gene set analysis 
β1-Integrinfl/fl livers vs β1-IntegrinWT livers after 7 days of recovery. Gene sets with a 
false discovery rate (FDR) below 0.05 are displayed.  N=3 biological replicates. 
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Table 4.1 – Gene sets associated with inflammation and injury response 
differentially expressed in β1-Integrinfl/fl livers compared to β1-IntegrinWT livers 
at day 7 of recovery 
Gene set p value 
Significant Genes (fold change + >3.5) compared to 
β1-IntegrinWT 
IL6 JAK 
STAT3 
signaling 
0.0001 
Csf2rb2 Il1b Cd14 Tnf Cd44 Tgfb1 Cxcl10 Jun Ltb Socs3 Il1r2 
Tnfrsf12a Ccr1 Cd9 Tlr2 Il3ra Pf4 Cxcl2 
p53 pathway 
0.0001 
Cdkn1a Krt17 Tgfb1 Atf3 Hbegf Inhbb Jun Lif Upp1 Ier3 Klf4 Fos 
Ralgds Procr Ier5 St14 S100a4 Nupr1 Phlda3 Tax1bp3 Def6 Btg2 
Vdr Sphk1 Dram1 Prmt2 Cdkn2b Ndrg1 
Apoptosis 
0.0001 
Cdkn1a Il1b Cd14 Tnf Cd44 Plat Emp1 Atf3 Clu Gna15 Jun Pak1 
Ier3 Gadd45b Pea15a Tnfrsf12a Btg2 Timp1 Lgals3 Egr3 Krt18 Rhob 
Gstm2 
TNFα 
signaling via 
NFKβ 0.0002 
Icam1 Cdkn1a Il1b Tnf Cd44 Dusp4 Cyr61 Tnfrsf9 Cxcl10 Areg Atf3 
Hbegf Fut4 Nr4a1 Jun Lif Nfkb2 Olr1 Ccl5 Ccl12 Ier3 Socs3 Bcl2a1b 
Klf4 Dusp5 Fos Tnfaip3 Relb Tnfaip6 Junb Gadd45b Fjx1 Ier5 Maff 
Clcf1 Pmepa1 Spsb1 Egr2 Tlr2 F2rl1 Gpr183 Tnip1 Fosb Btg2 Nfkbie 
Egr3 Sphk1 Dram1 Plaur Icosl Panx1 Tnc Plau Egr1 Serpine1 Rhob 
Gfpt2 Slc2a6 Cxcl5 Cxcl1 Cxcl2 Tubb2a 
Allograft 
rejection 0.0002 
Icam1 Il1b Tnf Ncf4 Tgfb1 Cd3e Flna Inhbb Lif Ltb Ccl2 Ccl5 Ccl12 
Cd74 Cd8b1 Mmp9 Fgr H2-DMa Cd7 Thy1 Map4k1 Ccl22 Ccl11 
Cd247 Itgb2 Ccr1 Elane Tlr2 Timp1 Capg Eif3j2 Hcls1 Il2rb Icosl 
Nos2 H2-DMb1 H2-DMb2 Pf4 H2-Aa Cd8a 
IL2 STAT5 
signaling 0.0002 
Cd44 Emp1 Tnfrsf9 Cxcl10 Etv4 Lif Ltb Rhoh Tgm2 Eomes Ckap4 
Ncs1 Gadd45b Il1r2 Maff Serpinb6a Capg Cst7 Plscr1 Il2rb Il3ra 
Ndrg1 Cdc6 Rhob Aplp1 Glipr2 Adam19 
Angiogenesis 0.0003 Thbd Olr1 Prg2 Fstl1 S100a4 Col5a2 Timp1 Col3a1 Pf4 Cxcl5 
Inflammatory 
response 0.0009 
Icam1 Cdkn1a Il1b Cd14 Scn1b Emp3 Tnfrsf9 Cxcl10 Hbegf Gna15 
Lif Olr1 Ccl5 Ccl12 Ccl17 Cx3cl1 Has2 Tpbg Tnfaip6 Ccl22 Gpr132 
Osm Adora2b Ptafr C5ar1 Slc7a1 Tlr2 Sema4d Gpr183 Btg2 Timp1 
Sphk1 Il2rb Plaur Icosl Serpine1 Cxcl5 Cmklr1 Ffar2 
UV response 
up 
0.0013 
Icam1 Amd2 Atf3 Nr4a1 Fos Tyro3 Junb Htr7 Fosb Btg2 Cdkn2b 
Rhob Cxcl1 
Complement 
0.0018 
Itgam Plat Clu Col4a2 Fcnb Ltf Olr1 S100a9 Ccl5 Dusp5 Pla2g7 
Tnfaip3 Maff Anxa5 Timp1 Lgals3 Csrp1 Plscr1 Plaur Serpine1 Pdgfb 
E2F targets 
0.0034 
Lig1 Cdkn1a Mcm3 Mcm2 Plk1 Cdkn3 Stmn1 Mcm6 Mcm5 Hn1 
Racgap1 Cdca3 Kif18b Mthfd2 Kif2c Cdca8 Kif22 Melk Espl1 Mxd3 
Birc5 Cdc20 Aurkb Asf1b Cdk1 Tubb5 Ccnb2 Tacc3 
Interferon γ 
response 0.0056 
Icam1 Ciita Cdkn1a Csf2rb2 Cxcl10 Ccl5 Ccl12 Upp1 Socs3 Cd74 
H2-DMa Tnfaip3 Tnfaip6 Itgb7 Mthfd2 Plscr1 Il2rb Xaf1 H2-Aa 
Cmklr1 
DNA repair 0.0072 Lig1 Hcls1 
Coagulation 
0.0144 
Thbd Plat Clu Itga2 Olr1 Mmp9 Maff Cd9 Fbn1 Sparc Thbs1 Capn5 
Timp1 Csrp1 Mmp11 Plau Serpine1 Pdgfb Pf4 
ROS 
pathway 
0.0254 Lsp1 Junb Mpo 
Table 4.1: MSigDB Hallmark Gene set analysis. FDR = false discovery rate and ROS 
= reactive oxygen species.  
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Table 4.2 – Gene sets associated with liver function differentially expressed in 
β1-Integrinfl/fl livers compared to β1-IntegrinWT livers at day 7 of recovery 
Gene set p value 
Significant Genes (fold change + >3.5) compared 
to β1-IntegrinWT 
Heme 
metabolism 0.0001 
Alas2 Top1 Selenbp2 Cir1 Aldh6a1 Klf1 Ell2 Dcun1d1 Car1 Myl4 
Fn3k Kdm7a Nr3c1 Daam1 Osbp2 Usp15 Hist2h4 
 Bile acid 
metabolism 0.0003 
Dio1 Abcd3 Cyp8b1 Idi1 Cyp7b1 Klf1 Slc27a5 Pnpla8 Abca1 
Cyp7a1 Acsl1 Scp2 Slc27a2 Nudt12 Akr1d1 Sult1b1 Abca6 
Hsd3b2 
 Fatty acid 
metabolism 
0.0092 
Dld Idi1 Tdo2 Hibch Adh7 Acsl1 Aadat Hsp90aa1 Acsm3 Cyp4a32 
Cyp4a12a Cyp4a12b 
 Adipogenesis 0.0114 Dld Chuk Dbt Lifr Omd Hibch Elovl6 Abca1 Scp2 
 Xenobiotic 
metabolism 
0.0219 Ptgds Tdo2 Angptl3 Ces1d Ttpa Adh7 Papss2 Cyp2e1 Hsd11b1 
Table 4.2: MSigDB Hallmark Gene set analysis. FDR = false discovery rate 
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Table 4.3 – Signalling gene sets differentially expressed in β1-Integrinfl/fl livers 
compared to β1-IntegrinWT livers at day 7 of recovery 
Gene set p value 
Significant Genes (fold change + >3.5) compared to 
β1-IntegrinWT 
IL6 JAK 
STAT3 
signaling 
0.0001 
Csf2rb2 Il1b Cd14 Tnf Cd44 Tgfb1 Cxcl10 Jun Ltb Socs3 Il1r2 
Tnfrsf12a Ccr1 Cd9 Tlr2 Il3ra Pf4 Cxcl2 
 PI3K AKT 
mTOR 
signaling 
0.0001 Cdkn1a Cxcr4 Sla Cdk1 
 Heme 
metabolism 
0.0001 
Alas2 Top1 Selenbp2 Cir1 Aldh6a1 Klf1 Ell2 Dcun1d1 Car1 Myl4 
Fn3k Kdm7a Nr3c1 Daam1 Osbp2 Usp15 Hist2h4 
 Estrogen 
response 
early 
0.0001 
Cd44 Areg Inhbb Wisp2 Klf4 Elf3 Tgm2 Hr Fos Tpbg Rab31 Cldn7 
Olfml3 Syt12 Slc1a4 Egr3 Myof Slc24a3 Adcy1 Sult2b1 Tubb2b 
Krt18 Krt8 
 TNFα 
signaling via 
NFKβ 0.0002 
Icam1 Cdkn1a Il1b Tnf Cd44 Dusp4 Cyr61 Tnfrsf9 Cxcl10 Areg Atf3 
Hbegf Fut4 Nr4a1 Jun Lif Nfkb2 Olr1 Ccl5 Ccl12 Ier3 Socs3 Bcl2a1b 
Klf4 Dusp5 Fos Tnfaip3 Relb Tnfaip6 Junb Gadd45b Fjx1 Ier5 Maff 
Clcf1 Pmepa1 Spsb1 Egr2 Tlr2 F2rl1 Gpr183 Tnip1 Fosb Btg2 
Nfkbie Egr3 Sphk1 Dram1 Plaur Icosl Panx1 Tnc Plau Egr1 
Serpine1 Rhob Gfpt2 Slc2a6 Cxcl5 Cxcl1 Cxcl2 Tubb2a 
 IL2 STAT5 
signaling 0.0002 
Cd44 Emp1 Tnfrsf9 Cxcl10 Etv4 Lif Ltb Rhoh Tgm2 Eomes Ckap4 
Ncs1 Gadd45b Il1r2 Maff Serpinb6a Capg Cst7 Plscr1 Il2rb Il3ra 
Ndrg1 Cdc6 Rhob Aplp1 Glipr2 Adam19 
 KRAS 
signaling up 0.0002 
Il1b Plat Scn1b Emp1 Cxcl10 Hbegf Etv4 Itga2 Kcnn4 Lif Slpi Il1rl2 
Klf4 Mmp9 Spon1 Tnfaip3 Laptm5 Map4k1 Tmem158 Lat2 F13a1 
Itgb2 Cxcr4 Wnt7a F2rl1 Ace Mmp11 Cpe Plaur Plau Aldh1a3 
Aldh1a2 Gfpt2 Adam8 Serpina3c Cmklr1 
 Estrogen 
response late 0.0003 
Cd44 Areg Ltf S100a9 Wisp2 Klf4 Cxcl14 Hr Fos Tpbg Rab31 Gjb3 
St14 Cd9 Slc1a4 Cdc20 Ckb Egr3 Kif20a Myof Gins2 Slc24a3 Chst8 
Cpe Sult2b1 Cdc6 Ptger3 Serpina3c 
 TGFβ 
signaling 
0.0004 Ltbp2 Tgfb1 Id1 Rab31 Junb Pmepa1 Thbs1 Serpine1 
 Notch 
signaling 
0.0005 Lfng 
 WNT β-
catenin 
signaling 0.0137 
Significant Genes (fold change + >2) compared to β1-
IntegrinWT 
Trp53 Jag2 Hey1 Nkd1 Fzd1 
Table 4.3: MSigDB Hallmark Gene set analysis. FDR = false discovery rate. 
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Wnt expression increased early in recovering β1-Integrinfl/fl livers 
Gene set analysis can be used to interpret whole genome data that has been generated 
from RNA-Seq.  This method utilises established sets of genes associated with a given 
biological process or cell signalling pathway and compares them to genes expressed 
in the various experimental groups. Differentially expressed genes that are 
significantly increased in a group are identified, revealing any active processes or 
signalling pathways present in the experiment. Using the conservatively curated 
‘MSigDB Hallmark gene set’290 the WNT-β-Catenin signalling pathway was identified 
as being upregulated in β1-Integrinfl/fl livers at day 7 of recovery. No WNT genes from 
this set had a large increase, i.e. >3.5-fold change, in expression. Therefore, I used the 
MSigDB canonical gene set, which has been curated by WNT specialists, to 
specifically analyse the WNT pathway in RNA-Seq data from DDC treated livers at 
day 7 of recovery.  
Gene set enrichment analysis of β1-Integrinfl/fl liver compared to β1-IntegrinWT liver 
at day 7 of recovery revealed an enrichment for upregulated WNT signalling genes 
(Figure 4.15a). 30 WNT genes from the β1-Integrinfl/fl liver had a >2-fold change in 
expression compared to β1-IntegrinWT liver. Wnt ligand genes: Wnt7a, Wnt11, Wnt7b, 
Wnt10a, Wnt4, Wnt 9a and Wnt2 were all upregulated in the β1-Integrinfl/fl liver, along 
with WNT modulators: Sfrp1, Frzb, Sfrp4, Nkd1. Wif1 and Apc express proteins that 
supress WNT signalling, both were downregulated in the β1-Integrinfl/fl liver. 6 WNT 
signalling receptors; Fzd3, Fzd2, Fzd1, Fzd4, Fzd8 and Lrp6 were also differentially 
expressed in the β1-Integrinfl/fl liver (Figure 4.15b). 
Whole liver qPCR was used to validate the RNA-Seq data and investigate Wnt (Wnt9b, 
Wnt7b, Wnt11, Wnt7a and Wnt10a) expression at other recovery time points. Wnt 
expression was equal between the β1-Integrinfl/fl and β1-IntegrinWT livers before injury 
and during DDC diet treatment. Wnt expression remained low in the β1-IntegrinWT 
liver, sharply contrasting the β1-Integrinfl/fl liver, where Wnt expression had a 2-4-fold 
increase (Figure 4.15c).  
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Figure 4.15 – Whole liver Wnt expression increased in the early phase of 
recovery when β1-Integrin is ablated  
 
Figure 4.15: a. MSigDB canonical gene set analysis, WNT signalling barcode plot; 
there is an enrichment for upregulated genes associated with the WNT pathway after 
DDC induced liver injury and 7 days of recovery. FDR = false discovery rate. b. Gene 
list from the ‘MSigDB canonical gene set: WNT signalling genes that have >2-fold 
change in expression in the β1-Integrinfl/fl liver compared to β1-IntegrinWT. N=3 
biological replicates c. Whole liver qPCR for major WNT lignads identified in RNA-
Seq analysis, data are mean ± s.e.m; N= 4 biological replicates per condition.   
Chapter 4 – Results 
 
105 
 
Discussion 
Hepatotoxic induced liver injury resulted in strikingly different regenerative responses 
from the β1-Integrinfl/fl and β1-IntegrinWT livers. When both genotypes were treated 
with DDC diet, liver injury was induced. The β1-IntegrinWT livers regenerated via self-
duplication of the tdTom labelled hepatocyte epithelium. This method of regeneration 
resulted in liver recovery 7 days after returning to normal diet, demonstrated by normal 
LFTs, body weight, and the absence of necrosis and p21 positive hepatocytes (Figure 
4.16a).  In contrast, the β1-Integrinfl/fl livers had a prolonged recovery; LFTs, body 
weight and the amount of p21pos hepatocytes did not return to normal (control) levels 
until day 14 of recovery. Tissue damage continued in the β1-Integrinfl/fl livers, with a 
large necrotic event occurring around day 3 of recovery. During this second phase of 
liver damage, a biliary derived, invasive, DR began to infiltrate the parenchyma 
(Figure 4.16b). Although tdTompos β1-Integrinfl/fl hepatocytes expressed proliferation 
markers they failed to completely regenerate the liver; as an alternative, a periportal, 
non-hepatocyte derived source responded, regenerating the hepatocyte epithelium.  
At day-14 of recovery in the β1-Integrinfl/fl liver, regardless of the type of injury, the 
hepatocyte epithelium was comprised from two distinct populations of hepatocytes. 
These populations were distinguishable by the fluorescent marker tdTomato. tdTompos 
hepatocytes were biased towards a pericentral location and originated from pre-injury 
hepatocytes that were β1-Integrin deficient. Small, proliferative, tdTomneg, β1-
Integrinpos hepatocytes appeared after injury at a periportal location. The periportal 
distribution of the tdTomneg hepatocytes along with the timing of their appearance, 
during an atypical DR, suggests that the tdTomneg hepatocytes may have a biliary 
origin.  
During recovery β1-Integrinfl/fl livers eventually stopped displaying markers of 
hepatocyte injury, with serum LFTs, HMGB1 staining and histological necrosis 
scoring returning to normal by day-14 of recovery. However, other parameters that 
were enhanced after DDC induced injury such as the elevated amount of CK19pos cells 
and liver fibrosis remained abnormally high. Indeed, the degree of fibrosis developed 
further with striking fibrous septa present throughout the parenchyma by day 42 of 
recovery. This incomplete recovery can be explained by the composition of the 
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hepatocyte epithelium, which after day 14 of recovery contained new tdTomneg 
hepatocytes and the remaining tdTompos, β1-Integrin deficient, hepatocytes. These 
defective hepatocytes were likely stimulating fibrosis and the continued presence of 
atypical ductal cells. Further to this point, the residual atypical ductal cells that were 
still present in the parenchyma after day 14 of recovery were predominantly distributed 
amongst the tdTompos, β1-Integrin deficient, hepatocytes.  
 
Figure 4.16 – Distinct regenerative responses between the β1-Integrinfl/fl and 
β1-IntegrinWT livers 
 
Figure 4.16: Frequency polygons displaying changes to key features observed 
throughout DDC induced liver injury and recovery. a. Frequency polygon for the β1-
IntegrinWT liver and normal regeneration after DDC treatment. b. Frequency polygon 
for the β1-Integrinfl/fl liver where regeneration occurs later from a non-hepatocyte 
source.  
 
Another feature observed at peak injury and the early phases of recovery (until day 7) 
in the β1-Integrinfl/fl liver was hepatocyte ductal-metaplasia. Previously labelled 
tdTom hepatocytes no longer expressed mature hepatocyte markers such as CYP2D 
and HNF4α and acquired a morphology similar to the invasive CK19pos biliary ductal 
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cells. Although these ductal like hepatocytes expressed the biliary marker SOX9, they 
did not express CK19, and so did not fully convert to biliary epithelial cells. 
Considering the presence of these ductal like hepatocytes two features strike me. One 
being their transient appearance during the height of liver injury, suggesting that this 
might be a pro-survival mechanism, previously hypothesised by Tarlow et al75. This 
pro-survival mechanism could be through either preservation of the ductal-metaplastic 
cell or enhanced regeneration of the liver by ductal-metaplastic hepatocytes. Font 
Bugarda et al discovered a regenerative hybrid hepatocyte, which express the ductal 
marker, SOX9, and can regenerate the hepatocyte epithelium under certain 
conditions166. The second point worth considering is the location of these ductal like 
hepatocytes, which is at the interface between the biliary epithelium and its respective 
niche. This raises the question; can hepatocyte identity be manipulated by the ductular 
reaction and its accompanying niche43? Notch signalling and YAP, a component of the 
Hippo pathway, have both been linked to hepatocyte metaplasia74,230. Stromal 
stimulated notch signalling regulates biliary fate in disease52,300 and development201–
203, and promotes biliary cell expansion during DR56. Furthermore, artificial, 
overexpression of the ‘notch intracellular domain’ in hepatocytes reprograms them 
towards a biliary fate74. It is therefore plausible that notch signalling, which is 
promoting biliary expansion in the DR, may have off target effects that induce 
neighbouring hepatocytes to undergo ductal-metaplasia. Doxycycline inducible 
activated-YAP has also been shown to reprogram hepatocytes to a biliary fate230, it is 
unknown how Hippo signalling functions during liver regeneration and how it might 
be related to the DR.  
Whole liver RNA-Seq was used to assay for potential factors and signalling pathways 
involved with the non-hepatocyte derived regeneration detected in β1-Integrinfl/fl livers 
at day-7 of recovery. Two previously reported important developmental signalling 
pathways52, Notch and Wnt/β-Catenin were identified.  The Wnt ligands Wnt11, 
Wnt7b and Wnt9b had increased gene expression at early time points in the recovering 
β1 Integrinfl/fl livers. These ligands have been linked to cholangiocarcinoma301 and 
hepatic development214,217 and descriptive work by Hu et al revealed many of these 
Wnt ligands are expressed around the DR302. WNT responsive cells have an important 
role in liver regeneration9,86, particularly in HPC differentiation to hepatocytes52. 
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However, non-canonical WNT signalling may also have a role in regulating the DR as 
6 non-canonical Wnt genes: Wnt11, Wnt4, Wnt7b, Jun, Rhou, Daam1 were highly 
expressed. These genes are commonly associated with WNT Planar cell polarity (PCP) 
pathway303,304 and may have a role in orchestrating the formation and direction of the 
DR. 
To summarise DDC diet caused liver damage to both the β1-IntegrinWT and β1-
Integrinfl/fl groups. Parameters associated with liver injury rapidly returned to normal 
in the β1-IntegrinWT group, where no indicators of liver damage could be detected after 
day-7 of recovery. Mice from the β1-Integrinfl/fl group had a delayed return to health, 
with markers of liver injury not returning to normal until day-14 of recovery.  Analysis 
of tdTomato labelled hepatocytes after liver injury showed that there was a non-
hepatocyte source of regeneration in the β1-Integrin ablated liver. The early periportal 
location of the tdTomneg hepatocytes and the accompanying ductular reaction 
suggested that the source of these new, non-hepatocyte derived, hepatocytes could be 
from the biliary epithelium. To investigate the origin of the new tdTomneg hepatocytes 
I will lineage trace biliary epithelial cells in a setting where hepatocytes are β1-Integrin 
deficient.  
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Biliary ductular cells regenerate the liver when 
hepatocyte regeneration is impaired by β1-Integrin 
loss 
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Introduction 
Impaired hepatocyte regeneration caused by ablation of hepatocyte β1-Integrin 
resulted in regeneration from a non-hepatocyte origin. I hypothesised that the source 
of these new hepatocytes was the biliary derived DR. To test this hypothesis, labelled 
BECs were lineage traced in parallel with hepatocyte Itgb1 suppression.   
BEC lineage tracing utilised a tamoxifen inducible Cre transgene specifically 
expressed in the biliary epithelium to activate tdTom (see chapter 2, Figure 2.1b). In 
combination with the BEC lineage tracing, a Cre/Loxp independent system was 
developed to target hepatocyte β1-Integrin expression and recapitulate the phenotype 
observed in the AAV8Cre-β1-Integrinfl/fl model. Interfering RNA (RNAi) molecules 
packaged in to lipid coated nanoparticles have been shown to specifically suppress 
Itgb1 expression in hepatocytes in vivo263,266. I decided to utilise this system in 
combination with the DDC and MCD injury models (Figure 5.1) to lineage trace the 
biliary epithelium in a setting where regenerating hepatocytes are impaired by 
deficient β1-Integrin expression.    
 
Figure 5.1 – Experimental timeline describing the strategy to lineage trace 
biliary epithelial cells during nanoparticle-RNAi mediated suppression of Itgb1 
 
 
Along with determining the origin of the non-hepatocyte derived regeneration it is also 
important to compare the new tdTomneg hepatocyte population with, regular, 
hepatocytes that have regenerated by cell division. Through comparisons of global 
gene expression, I can determine if the new tdTomneg hepatocyte population have the 
same phenotype as regular hepatocytes. This experiment was done in collaboration 
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with Dr. Wei-Yu Lu, Centre for Regenerative Medicine; who had also developed a 
model to lineage trace CK19pos BECs in to hepatocytes by inducing cell cycle arrest in 
the hepatocyte epithelium using an AAV8-TBG-p21 virus with the K19CreERT 
LSLTdTomato mouse284. We therefore, designed an experiment that used the MCD diet 
to stimulate liver regeneration and isolated hepatocytes from the regenerated livers. 
From a C57Bl/6 genotype we harvested hepatocytes that had regenerated through self-
duplication and cholangiocytes (BEC) as a comparative control. The other two 
populations consisted of the BEC derived tdTompos hepatocytes (BDhepatocytes) from 
Dr Wei-Yu Lu’s AAV8-p21 model and the tdTomneg hepatocytes from the AAV8cre-
β1-Integrinfl/fl model. This allowed for a direct comparison between BEC derived and 
non-hepatocyte derived hepatocytes in relation to normal hepatocytes and BECs.  
Firstly, this chapter aims to ascertain the cellular source of regeneration when 
hepatocyte regeneration is impaired by loss of β1-Integrin through biliary epithelial 
lineage tracing. Secondly, this chapter will describe how biliary derived and non-
hepatocyte derived hepatocytes compare to control hepatocytes and biliary ductular 
cells using whole genome RNA-Sequencing.  
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Results  
Validation of the nanoparticle formulated RNAi and the inducible K19CreERT 
LSLtdTomato transgene 
To lineage trace BECs a K19CreERT LSLtdTomato transgene was activated by 
administering three 4mg doses of tamoxifen via intraperitoneal injection over 5 days 
(Figure. 5.1), the liver was harvested 19 days later to confirm the specificity of the 
labelling system. Tamoxifen induced tdTom expression specifically in HNF1βpos 
BECs (Figure 5.2a, magenta arrowheads) and could not be detected in any other liver 
cell type prior to MCD or DDC induced liver injury.  
To suppress hepatocyte β1-Integrin expression 9 days after the last tamoxifen 
injection, two doses of 0.5mg/kg RNAi nanoparticles were administered intravenously 
(IV) at 5 day intervals. 10 days after the first RNAi nanoparticle injection there was a 
visible reduction in hepatocyte β1-Integrin, at protein level (Figure 5.2b). In 
comparison, the control, anti-luciferase RNAi, which targets the absent luciferase 
gene, maintained hepatocyte β1-Integrin expression.  
Together, this data demonstrates that the K19CreERT LSLtdTomato transgene in 
combination with RNAi nanoparticles enables BEC lineage tracing and simultaneous 
hepatocyte β1-Integrin suppression.  
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Figure 5.2 – K19TomCreERT LSLtdTomato labels HNF1βpos BECs and RNAi 
nanoparticles knock down hepatocyte β1-Integrin expression  
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Figure 5.2: K19CreERT LSLtdTomato livers treated with 3X4mg doses of tamoxifen and 
two 0.5mg/kg, IV, doses of either anti-luciferase or anti-β1-Integrin RNAi 
nanoparticles. a. tdTom/HNF1β dual immuno-fluorescence confocal images, 
HNF1βpos BECs are labelled tdTompos – magenta arrowheads. b. β1-Integrin 
immunohistochemistry, images were captured with identical microscope settings. 
Isotype control refers to sample treated with rabbit IgG, which replaced the rabbit anti-
Itgb1 antibody. Scale bars: 100µM. 
 
 
 
Conventional murine liver injury models do not induce biliary derived 
regeneration  
K19CreERT LSLtdTomato induced labelling of BECs does not result in the emergence of 
tdTompos hepatocytes after liver injury caused by commonly used mouse hepatoxic 
injury diets: DDC, MCD and choline deficient ethionine supplemented (CDE) diet 
(toxic injury diet that models steatosis, DR, fibrosis and inflammation) (Figure 5.3).  
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Figure 5.3 – Traditional murine HPC inducing liver injury models do not result 
in BEC derived hepatocyte regeneration 
 
 
 
Figure 5.3: tdTomato immunohistochemistry of K19CreERT LSLtdTomato livers that 
were injured using the DDC, MCD and CDE hepatoxic liver injury diets. 
Corresponding experimental timelines are displayed adjacent to images of each injury 
model. Scale bars: 100µM. 
 
 
Chapter 5 – Results 
 
116 
 
Itgb1 knock down in hepatocytes provokes biliary derived regeneration of the 
hepatocyte epithelium 
Lipidoid-based nanoparticles specifically target hepatocytes suppressing Itgb1 
expression for 5days263,266, resulting in significant β1-Integrin decreases at a protein 
level after 10 days (Figure 5.2b). I therefore, began the liver injury diets 10 days after 
the first nanoparticle injection. To induce liver injury and stimulate hepatocyte 
regeneration, nanoparticle treated K19CreERT LSLtdTomato mice where given either 
MCD or DDC diet for 12 days (Figure 5.1).  
Livers treated with the anti-β1-Integrin RNAi had small patches of tdTompos/HNF4αpos 
hepatocytes adjacent to the PT (Figure 5.4). In contrast, no tdTompos hepatocytes were 
detected in the anti-luciferase RNAi treated livers. New tdTompos hepatocytes were 
adjacent to panCKpos/tdTompos BEC, there periportal location was confirmed by their 
E-Cadherin expression.  
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Figure 5.4 – Hepatocyte Itgb1 suppression combined with liver injury induces 
biliary derived hepatocyte regeneration 
 
Figure 5.4: HNF4α/tdTom/E-Cadherin and panCK/tdTom/E-Cadherin 
immunofluorescence and anti-RFP immunohistochemistry reveals biliary to 
hepatocyte lineage tracing in RNAi β1-Integrin treated liver. RNAi β1-Integrin = 
samples that received nanoparticles containing interfering RNA against Itgb1. RNAi 
luciferase = control samples that received nanoparticles containing interfering RNA 
against the absent luciferase gene. Scale bars: 100µM. 
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Transcriptome comparison between hepatocyte derived hepatocytes and 
ductal derived hepatocytes 
To compare distinct hepatocyte populations that have regenerated from alternative 
sources, livers were injured with MCD diet and hepatocytes were isolated using 
fluorescence activated cell sorting (FACS) (Figure 5.5a). Prior to FACS hepatocytes 
were purified using a Percoll gradient. Purified, living, hepatocytes were then selected 
using the gating strategy in Figure 5.5b, tdTompos or tdTomneg hepatocytes were 
selected using gates established from control, C57BL/6, hepatocytes. Validation, using 
cytospins and immunofluorescence, revealed cells isolated by FACS were HNF4αpos, 
and were either tdTompos or tdTomneg depending on the population that was selected 
(Figure 5.5c). 
100,000 cells from each population were collected during FACS, sorted cells were 
lysed and extracted RNA was sequenced by the Wellcome Trust Clinical Research 
Facility at the Institute of Genetics and Molecular Medicine. Analysis of the global 
transcriptional state for each cell population revealed biliary derived hepatocytes 
(BDhepatocytes) from AAV8-p21 treated livers and tdTomneg hepatocytes from the 
β1-integrinfl/fl model were highly similar to hepatocytes and distinct from ductal cells 
(Figure 5.6 a and b). BDhepatocytes from the AAV8-p21 model clustered more closely 
with control hepatocytes than the tdTomneg hepatocytes from the β1-integrinfl/fl model. 
Selected genes associated with the hepatocyte and biliary phenotype, and WNT and 
notch signalling in the liver were analysed between the different populations. Control 
hepatocytes and BDhepatocytes had a clear hepatocyte gene expression profile, while 
the tdTomneg cell gene expression profile was mixed, expressing both hepatocyte and 
biliary genes (Figure 5.7b).  Both WNT and notch signalling appeared upregulated in 
the cholangiocytes and tdTomneg hepatocytes when compared to control and 
BDhepatocytes (Figure 5.7b). Differences seen between the tdTomneg hepatocytes, the 
BDhepatocytes and the control hepatocytes were also detected with a ‘phase 1 drug 
metabolism enzymes’ qPCR array (Figure 5.7c), confirming the results from the RNA-
Seq experiment.  
Differences between the tdTomneg hepatocytes from the β1-integrinfl/fl model and the 
BD hepatocytes from the AAV8-p21 model were predominantly seen in: inflammatory 
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response, cell cycle, cell adhesion, negative regulation of apoptotic process, and 
oxidation-reduction process gene sets (Table 5.1).  
The FACS and RNA-Seq experiments were part of collaborative work performed in 
conjunction with Dr Wei-Yu Lu. Bioinformatics and analysis of the RNA-Seq data 
was carried out by Dr John Thomson at the MRC Human Genetics Unit. 
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Figure 5.5 – Strategy to Isolate hepatocytes for whole transcriptome analysis 
 
 
Figure 5.5: a. Schematic to isolate cells from three different mice genotypes that have 
received MCD induced liver injury for RNA-Seq analysis. b. FACS gating strategy to 
identify tdTompos and tdTomneg hepatocytes. c. Cell cytospins and tdTom/HNF4α 
immunofluorescence of FACS samples to verify correct gating strategy. Scale bars: 
100µM. 
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Figure 5.6 – Global transcriptome expression profiles from hepatocytes that 
have regenerated from distinct sources 
 
Figure 5.6: a. Pearson’s correlation matrix comparing non-hepatocyte derived, 
tdTomneg, hepatocytes (C) to BEC derived tdTompos hepatocytes (A) and control BEC 
(D) and hepatocytes (B). b. 3D principal component analysis comparing non-
hepatocyte derived, tdTomneg, hepatocytes (blue) to BEC derived tdTompos 
hepatocytes (red) and control BEC (green) and hepatocytes (black). Control-
hepatocytes from C57BL/6. N=3 biological replicates per condition. 
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Figure 5.7 – Drug metabolism qPCR array and select genes from RNA-Seq 
reveal differences between tdTomneg hepatocytes from the β1-Integrinfl/fl model 
and biliary derived hepatocytes from the AAV8p21 model 
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Figure 5.7 – continued  
 
Figure 5.7: a. Visual examples of average RNA-Seq transcriptional reads in sample 
groups across select loci. b. RNA-seq generated Z-score heatmaps with hierarchical 
clustering across specific gene sets. Heatmaps display gene expression levels 
normalized to each gene. c. qPCR array for phase 1 drug metabolism enzymes. 
Controls-hepatocytes are from C57BL/6 mice. N=3 biological replicates per condition. 
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Table 5.1 – Gene set analysis comparing tdTomneg hepatocytes from the β1-
Integrinfl/fl model and biliary derived hepatocytes from the AAV8p21 model 
Gene set p value Significant Genes 
Inflammatory 
response 
0.0000000039 
Axl, Clec7a, Cd14, Cd5l, Elf3, Aif1, Relb, Ccl2,Ccl6, Ccr2, 
Ccrl2, Cxcl10, Cxcl2, Cela1, Csf1r, Cyba, Cybb, Hck, Ly86, 
Ncf1, Nfkb2, Nfkbiz, Spp1, Tlr2, Tnfaip3 
Cell cycle 0.0000016 
Nek2, Racgap1, Src, Ajuba, Mki67, Aurka, Aurkb, Birc5, 
Cdca3, Ccna2, Ccnb1, Ccnb2, Ccnd1, Cdk1, Cdkn1a, 
Cdkn2c, Ect2, Esco2, Kif11, Mcm3, Mcm5, Mcm6, Nedd9, 
Ncapd2, Prc1, Rgs2, Smpd3, Ube2c, Uhrf1 
Cell adhesion 0.0000023 
Cd24a, Cd44, Cd63, Cd9, Ephb4, Src, Adgre5, Ajuba, 
Cadm4, Cx3cr1, Ctgf, Itga5, Itga6, Itgax, Itgb2, Lama5, 
Mfge8, Myh10, Nedd9, Nid1, Spp1, Sorbs3, Tgfbi, Tnfrsf12a, 
Vcam1 
Negative 
regulation of 
apoptotic 
process 
0.00001 
Axl, Bcl2a1b, Cd44, Cd74, Nat8, Nckap1l, Src, Sox9, 
Tsc22d1, Aif1, Asns, Aurka, Birc5, Csf1r, Cdk1, Cdkn1a, 
Fabp1, Flna, Gstp1, Hck, Ier3, Map4k4, Plac8, Rgn, Spp1, 
Ucp2 
Oxidation-
reduction 
process 
0.001 
Sdr9c7, Adh4, Akr1c14, Blvrb, Cyp2a12, Cyp2c29, Cyp2c50, 
Cyp2c54, Cyp2e1, Cyp2u1, Cyp2c37, Cyp4a12a, Cyp7b1, 
Cyp8b1, Cyba, Cybb, Dhrs9, Fam213a, Gpx7, Hsd3b5, 
Hsd11b1, Rrm2, Sord, Scd2 
Table 5.1: Top 5 gene ontology (GO) terms, analysis of differentially expressed genes 
between hepatocytes from β1-Integreinfl/fl and AAV8-p21 livers. 
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Discussion 
Impaired hepatocyte regeneration, mediated by β1-Integrin ablation, resulted in liver 
regeneration from a biliary origin. When hepatocyte regeneration is not impaired, as 
seen in the in the AAV8cre-β1-IntegrinWT model and anti-luciferase RNAi treated 
livers, there is no biliary contribution to hepatocyte regeneration.  
The two-step approach to both label BECs and knock down hepatocyte β1-Integrin 
expression caused small periportal patches of tdTompos hepatocytes to appear after 
hepatoxic diet induced liver injury.  The prolonged, RNAi mediated, method to 
suppress β1-Integrin expression was not as robust as the AAV8cre-β1-Integrinfl/fl 
model. Seven IV tail vein injections over a 35-day period leads to collapsed veins in 
the mouse tail and did occasionally result in a failed injection at the later time points, 
disrupting the phenotype and producing variability between each sample. Another 
limitation of the RNAi method was that it caused partial β1-Integrin ablation unlike 
the AAV8Cre-β1-Integrinfl/fl model where all hepatocyte β1-Integrin expression was 
lost, which could explain the observed, moderate, phenotype. Also, the K19CreERT 
LSLtdTomato transgene has a 40% labelling efficiency in the biliary epithelium284, 
therefore, the degree of BEC to hepatocyte differentiation may be higher than detected. 
For these reasons, direct comparisons of hepatocyte regeneration between the 
AAV8cre-β1-Integrinfl/fl model and the nanoparticle-K19CreERT LSLtdTomato model are 
not ideal. However, the nanoparticle-K19CreERT LSLtdTomato model does provide 
evidence, as a proof of principle, that hepatocyte β1-Integrin loss results in BEC 
derived regeneration of the hepatocyte compartment. One can therefore infer that in 
the AAV8cre-β1-Integrinfl/fl model tdTomneg hepatocytes are biliary derived.  
Transcriptional analysis of regenerated hepatocytes revealed that BDhepatocytes from 
the AAV8-p21 model and tdTomneg hepatocytes from the AAV8cre-β1-Integrinfl/fl 
model were closely related to hepatocytes and distinct from BECs. However, with 
stricter clustering it was apparent that tdTomneg hepatocytes were different to the 
control and BDhepatocytes. The tdTomneg hepatocytes maintained expression of some 
BEC markers and had an increase in notch associated genes, which have been 
previously shown to induce a biliary phenotype74,158. Further to this, the top 5 GO 
terms identified between the tdTomneg hepatocytes and BDhepatocytes such as 
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inflammatory response, cell cycle, and negative regulation of apoptotic process, are 
associated with liver injury. The fact that liver injury is not completely resolved in the 
β1-Integrinfl/fl model, as discussed in chapter 4, because of the continued presence of 
defective, β1-Integrin deficient, hepatocytes may account for the transcriptomic 
differences seen between the tdTomneg hepatocytes and the control/BDhepatocytes. 
Another, explanation for the differences between BDhepatocytes from the AAV8-p21 
model and tdTomneg hepatocytes from the AAV8cre-β1-Integrinfl/fl model could come 
from the isolation protocol. During FACS, hepatocytes were selected by their size, no 
cell surface markers were used to specifically select hepatocytes. It is therefore 
possible some contamination occurred and the tdTomneg cell population was not 
completely pure.  
Another interesting difference between the control hepatocytes and the tdTomneg and 
the BDhepatocytes, identified through hierarchical clustering, were alterations in Wnt 
signalling. Explanations for this difference could be attributed to the spatial 
distribution of the various hepatocyte types along the PT-CV axis. The BDhepatocytes 
and the tdTomneg hepatocytes were predominantly arranged around the PT in zone 1, 
a WNT low compartment of the liver8,305. In contrast the control hepatocytes would 
have been composed from a random collection of hepatocytes from all 3 liver zones, 
which may account for the differences.   
To conclude, the origin of tdTomneg hepatocytes in the AAV8cre-β1-Integrinfl/fl model 
was from the biliary epithelium; confirmed by BEC lineage tracing with concurrent, 
RNAi mediated, hepatocyte Itgb1 suppression. tdTomneg hepatocytes that regenerate 
the liver in the AAV8cre-β1-Integrinfl/fl model transcriptionally cluster relatively close 
to control hepatocytes but do continue to display some BEC characteristics, possibly 
induced by the continued presence of liver injury.  
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Liver disease, a growing health risk in the UK15, can evolve to liver cirrhosis or liver 
cancer, for which the only effective treatment is a liver transplant. A scarcity of liver 
organ donors however impedes and prevents patient treatment. Therefore, therapeutic 
alternatives are required to treat the growing incidents of liver cirrhosis. Enhancing 
endogenous liver regeneration is an attractive approach to treating liver disease, as it 
avoids complications that arise from cell and tissue transplantation therapies, 
particularly the use of immunosuppressant medicines. During human chronic liver 
disease, the hepatocyte compartment can no longer regenerate efficiently because of 
increased levels of parenchymal cell cycle arrest and senescence34,36,306. Concurrently, 
a periportal DR of unknown epithelial origin arises37,42,61 and can hypothetically 
regenerate the hepatocyte epithelium70. To determine the regenerative potential of the 
DR and identify the types of epithelial cells and molecular signalling systems 
regulating DR mediated regeneration we need a suitable murine lineage tracing model. 
Investigations of  DR derived hepatocyte regeneration using mouse lineage tracing 
models have challenged the postulated regenerative potential of the DR56,156,157,159. A 
new theory, suggests that the DR is composed from both BECs and hepatocytes 
undergoing ductal metaplasia. The reversion of metaplastic hepatocytes back to a 
hepatocyte phenotype imitates biliary derived regeneration of the hepatocyte 
compartment75, and actual biliary derived regeneration is minimal, less than 2%150,156. 
However, commonly used mouse liver injury models do not recapitulate human liver 
disease as they do not cause hepatocyte senescence or impair hepatocyte mediated 
regeneration87,156.  
The purpose of this PhD thesis therefore, was to determine if cells in the biliary 
epithelium can regenerate the hepatocyte epithelium. I hypothesised that impairing 
hepatocyte regeneration, via ablation of β1-Integrin, will induce biliary derived 
regeneration of the hepatocyte compartment. Using two independent lineage tracing 
techniques, I have ascertained that a non-hepatocyte source of regeneration from the 
biliary epithelium can regenerate hepatocytes, when a β1-Integrin deficient hepatocyte 
epithelium is injured and fails to regenerate. These findings support data from human 
liver pathology studies42 and PH-AAF experiments in rat44,171, which link HPC and 
DR derived regeneration with an impaired hepatocyte regenerative response.  
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The first aim of this thesis was to impair hepatocyte regeneration and lineage trace the 
hepatocyte compartment. Using: AAV8.TBG.Cre to induce a robust genetic 
recombination efficiency, a ROSA26LSLtdTomato reporter, and conditional Itgb1fl/fl 
alleles that enable specific ablation of β1-Integrin; I lineage traced hepatocytes and 
simultaneously impaired hepatocyte regeneration. This experimental model revealed 
an essential requirement for hepatocyte β1-Integrin expression during homeostasis. 
The β1-Integrinfl/fl livers displayed markers of chronic liver injury and hepatocytes 
were regenerated from a non-hepatocyte source. Further analysis of the hepatocyte β1-
Integrinfl/fl phenotype revealed a delayed regenerative response after hepatotoxic 
insult. Recovery of β1-Integrinfl/fl livers coincided with an infiltrating, expanding, DR 
and the emergence of periportal, non-hepatocyte derived, hepatocytes, which 
regenerated 25% of the parenchyma. Although hepatocyte ductal metaplasia occurred 
at peak injury and early in recovery, they were not the source of regeneration as the 
new hepatocytes were tdTomato negative.  
To ascertain the origin of non-hepatocyte derived regeneration in the β1-Integrinfl/fl 
liver and address aim two of this thesis, BECs were lineage traced in a setting where 
hepatocyte Itgb1 expression was knocked down. A K19CreERT LSLTdTomato transgene 
was used to lineage trace BECs and lipid coated RNAi nanoparticles were employed 
to target hepatocyte β1-Integrin expression. Hepatocyte β1-Integrin knockdown and 
liver injury induced BEC differentiation to a hepatocyte fate, supporting the theory 
that new hepatocytes produced in the AAV8Cre-β1-Integrinfl/fl experiments were biliary 
derived. 
Whole genome comparisons between non-hepatocyte derived hepatocytes (tdTomneg 
hepatocytes) from the AAV8Cre-β1-Integrinfl/fl model, BDhepatocytes, control BECs 
and control hepatocytes showed tdTomneg and BDhepatocytes were more like 
hepatocytes on a transcriptomic level than BECs. Furthermore, tdTomneg hepatocytes 
had a hepatocyte morphology and expressed mature hepatocyte markers at a protein 
level. Together, these findings demonstrate that non-hepatocyte derived regeneration 
from a biliary origin produces functional hepatocytes.  Although, underlying 
inflammation and fibrosis caused by remaining β1-Integrin deficient hepatocytes in 
the AAV8Cre-β1-Integrinfl/fl model may explain why the tdTomneg hepatocytes were, to 
a small degree, different to control hepatocytes and BDhepatocytes. 
Chapter 6 – Conclusions and future perspectives 
 
130 
 
 
Developmental pathways; Hippo, Wnt, Notch, have all been shown to regulate cell 
fate in the liver52,74,230. However, it is unknown how these signalling pathways 
integrate with a scenario where hepatocyte regeneration is impaired and biliary derived 
regeneration takes over. The next big question that follows this thesis should ask: how 
does an environment where hepatocyte regeneration is impaired signal to BECs in the 
ducts to induce hepatocytic differentiation? The signalling axes regulating this process 
may be direct, between the defective hepatocytes and the BECs, or may be working 
indirectly, via the niche that surrounds BECs and DR (Figure6.1).  
  
Figure 6.1 – What is the signalling axis between hepatocytes that cannot 
regenerate and the biliary derived HPC that differentiates to a hepatocyte fate? 
 
Figure 6.1: Schematic highlighting unknown mechanisms regulating hepatic 
progenitor cell (HPC) mediated regeneration when the hepatocyte epithelium cannot 
regenerate. 
 
One prominent candidate that may influence BEC fate is the hepatocyte derived 
senescence associated secretory phenotype (SASP), as many senescent hepatocytes are 
present in human liver disease35,36. The SASP has been shown to promote cell 
plasticity and promote regeneration in the epidermis and liver307. Also, recent in vivo 
cell re-programming experiments have described enhanced pluripotent 
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reprogramming in cells exposed to the SASP of neighbouring senescent cells308,309. IL-
6 activity was identified as a component that improved re-programming; interestingly, 
IL-6 signalling was a top hit in the gene set analysis of whole liver RNA-Seq from 
recovering β1-Integrinfl/fl livers. How IL-6, or the SASP in general, promote re-
programming is currently unknown. Chromatin rearrangement towards an open 
chromatin state have been shown to facilitate cell re-programming in vitro310,311. It 
would be worth investigating whether a permissive SASP increases chromatin 
openness in the BECs and DR during liver disease. One could hypothesise that high 
levels of senescent hepatocytes produce a SASP that primes BECs for hepatocytic 
differentiation. To test this hypothesis, BECs could be isolated from senescent livers 
and then sequenced using ATAC-Seq, to reveal any changes in open chromatin and 
identify the altered locations on the BEC genome when compared to BECs from a 
control (non-senescent) liver. Another, simpler experiment, could involve either co-
cultures with senescent hepatocytes and non-senescent BEC, or culturing BECs with 
conditioned medium from senescent hepatocytes, to identify any direct effects 
senescent hepatocytes have on BECs.  
Systemic regulation of liver size and mass was previously mentioned as an important 
factor in liver growth133,134. Regulatory pathways that control liver size have been 
thought to act predominantly on the hepatocyte epithelium135,312. However, one could 
raise the question; if the hepatocyte epithelium fails to respond to these accumulating 
‘hepatostat’ signals, do the BECs in the DR respond by differentiating in to new 
hepatocytes? 
In relation to hepatostat signalling, recent work has identified a form of quorum 
sensing in the epidermis which directs regeneration according to the degree of damage. 
Quorum sensing was originally identified in bacteria and is a system where stimuli and 
response is coupled to population density313. In the epidermis, regeneration via a 
CCL2-macrophage- TNFα axis was only stimulated at a specific threshold of 
damage314. Perhaps a similar mechanism exists in the liver, where a certain threshold 
of senescent hepatocytes are needed to activate BEC derived regeneration. 
The Hippo pathway can regulate organ size141 and cell fate in the liver, overactivation 
of YAP in hepatocytes re-programmes them to a biliary fate230. Normally, YAP 
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expression is bimodal, BECs display strong nuclear YAP expression in contrast to the 
hepatocytes that express YAP at lower levels230. The activation of YAP is dependent 
on bile salt concentration in the liver312,315, potentially explaining the bimodal 
expression between the two liver epithelia. Although, the ECM and physical 
stimulus142 can also regulate the Hippo pathway, therefore multiple factors may be 
controlling the Hippo pathway in the liver. Indeed, the ECM surrounding hepatocytes 
is distinct to the ECM around BECs, the latter, for example is rich in laminins44. Also, 
Hippo signalling during hepatic development modulates enhancers that influences 
HNF4α and FOXA2 binding206. One could therefore hypothesise that loss of either the 
ECM or bile rich environment at the bile ducts reduces YAP activation in the BEC 
promoting hepatocytic differentiation. Data from Yimlamai et al supports this theory; 
in an artificial model where YAP expression could be controlled via a doxycycline 
sensitive transgene Yimlamai et al showed that hepatocytes with high YAP become 
BECs. Removal of doxycycline, resulted in loss of YAP activation and 20% of the 
converted BECs reverting back to hepatocytes230. However, the 20% reversion may be 
caused by incomplete hepatocyte re-programming and not caused by changes in YAP 
expression. An experimental, transgenic, model that enables YAP modulation in the 
biliary epithelium would determine the validity of this hypothesis. 
Whole liver qPCR and RNA-Seq identified an increase in Wnt signalling during the 
emergence of tdTomneg hepatocytes in the β1-Integrinfl/fl model. Many of the identified 
Wnt ligands are expressed around the DR302, although little is known about the 
functional roles of these Wnt ligands in liver regeneration. Canonical WNT/β-Catenin 
signalling is involved in hepatocyte differentiation and zonal specification5,7,8, 
therefore some of the Wnt genes may have a role in promoting BEC differentiation to 
an hepatocyte fate. However, some of the identified Wnt genes are also involved in the 
non-canonical PCP pathway, suggesting WNT signalling may be carrying out multiple 
functions during DR derived liver regeneration such as: promoting proliferation, 
directing cell fate and organising BEC polarity in the DR.  
In the introduction, I highlighted the many mechanisms that regulate cell fate during 
hepatic development. Future investigations should aim to determine if, or, how 
developmental signals might integrate in to the paradigm of biliary derived HPC 
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regeneration. For example, endothelial cells are essential for hepatic organogenesis184 
and are also a constituent of the adult HPC niche46, yet no one has investigated if 
endothelial cells have a role in HPC mediated regeneration. Epigenetic changes 
probably have an important role in HPC mediated regeneration, as research in the 
neonate has revealed. Neonatal downregulation of the microRNA, Mir122, by the BEC 
transcription factor GRHL2 restricts biliary derived HPC differentiation in to 
hepatocytes227. Reversal of this regulatory mechanism, when hepatocyte regeneration 
is impaired, may be one mechanism that facilitates HPC regeneration.  Finally, 
developmental studies have carefully dissected out the regulatory transcription factors 
that control hepatic fate5. Of particular relevance are the pioneer transcription factors 
Foxa1/2, which establish new gene programmes that induce hepatic 
differentiation186,191. Pioneer transcription factors regulate cell fate during regeneration 
and cancer formation316–319. Therefore, future work should consider which pioneer 
transcription factors are involved with HPC differentiation and how they are 
influenced by impaired hepatocyte regeneration.   
 
The biliary epithelium can regenerate hepatocytes in a mammalian model of impaired 
hepatocyte regeneration. However, questions remain, can all BECs regenerate the 
hepatocyte epithelium? Or is there a specialised subset of BECs that can behave as 
HPCs? Or is it solely, the proposed HPC that resides in the Canal of Hering between 
the biliary ductules and the hepatocyte epithelium? BECs are heterogeneous, a subset 
of BECs, express high levels of CD13387, ST14 (suppression of tumorigenicity 14)320, 
or are EpCAM positive and upregulate LGR586,89; these populations can form colonies 
and self-renew in vitro and can, competitively, repopulate the liver after 
transplantation.  
In vivo studies of the intrahepatic biliary network have revealed significant biliary 
remodelling in response to liver injury321. Fate tracing of CD133 positive BECs using 
3D imaging showed that BEC growth was stochastic, meaning there was no stem cell 
hierarchy, BECs could enter or terminate a growth phase suggesting the proliferating 
BEC sub-population was not fixed322. Together, in vitro and in vivo investigations of 
BECs have revealed heterogeneity, and the presence of a proliferative subpopulation 
Chapter 6 – Conclusions and future perspectives 
 
134 
 
of cells. It is unknown if BEC heterogeneity is fixed regarding changes in cell fate, 
there appears to be a degree of plasticity regarding proliferative BEC subpopulations, 
as BECs can enter or exit a proliferative state. It is possible a similar degree of 
plasticity occurs when BECs become primed to differentiate in to hepatocytes.  
The dynamics of biliary epithelial mediated regeneration is still unknown; future 
works should determine if the bulk of hepatocyte regeneration comes from biliary 
differentiation; or the production of small clusters of healthy biliary derived 
hepatocytes that proliferate, amplifying their population size to regenerate the liver. In 
the human, hepatocyte clusters adjacent to the DR have increased HGF and EGF 
activity323, suggesting new biliary derived hepatocytes are stimulated further to expand 
their population size. The proliferation dynamics of the, new, tdTomneg hepatocytes in 
the AAV8Cre-β1-Integrinfl/fl model could be determined using nucleotide analogues 
BrdU and EdU to sequentially label proliferating cells. Identifying any cells that are 
continuously dividing as they would be dual positive for BrdU and EdU. 
 
This PhD thesis failed to fully describe the mechanisms involved in hepatocyte β1-
Integrinfl/fl mediated pathogenesis. The literature indicates that there could be multiple 
effects produced by deleting β1-Integrin from hepatocytes. Further work is required to 
explain the exact mechanism causing liver damage, particularly in a setting where 
there are no hepatotoxins. Defining the β1-Integrinfl/fl mediated pathophysiology is 
important as it would reveal how different this mouse liver injury model is to chronic 
liver disease in the human. A greater understanding of the pathophysiology may also 
reveal or provide clues to which factors and processes in the liver micro-environment 
induce biliary epithelial duct cells to become hepatocytes.  
The β1-Integrinfl/fl phenotype induced fibrosis and a reduction in the number of 
labelled hepatocytes. Further experiments over a longer period, 6-12months, should 
be performed to determine if all the tdTompos/β1-Integrinfl/fl hepatocytes are 
completely replaced by the biliary derived tdTomneg hepatocytes. Furthermore, the β1-
Integrinfl/fl model of chronic liver disease should be investigated to determine if the 
chronic injury environment evolves into liver cancer. There is no obvious oncogene 
inducing mechanism from the loss of β1-Integrin and based upon previous studies 
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investigating cell growth in the liver, loss of β1-Integrin should have a negative impact 
on cancer formation266. However, the theory that an environment of chronic injury can 
induce liver cancer could be investigated with this model as it excludes the added 
complications of introducing a transgenic oncogene or carcinogenic molecule that 
mutates DNA. Also, the tdTomato labelling would lineage trace tumour origin, to 
determine if biliary derived (tdTomneg cells) or hepatocytes (tdTompos) contribute to 
tumorigenicity; recent data suggests malignant HCC predominantly arises from 
hepatocytes and not biliary derived DR324.  
 
This thesis has clarified the regenerative potential of the DR, demonstrating that in a 
setting of impaired hepatocyte regeneration BECs can produce new hepatocytes. This 
correlates with human liver pathology, where DRs producing new hepatocyte buds 
increases as the hepatocyte compartment becomes senescent. Now we know impaired 
hepatocyte regeneration is an essential pre-requisite for biliary derived regeneration, 
we can begin to investigate regulatory processes that control changes in liver cell fate. 
This work will advance our understanding of liver regeneration and may produce 
therapeutic targets that promote DR derived regeneration and hepatocytic 
differentiation. 
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